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General Introduction 
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Angiogenesis is the process in which new blood vessels are formed from pre-existing vessels. 
The purpose of angiogenesis is to provide oxygen and nutrient and to remove waste products. 
This process is essential in embryogenesis, and in healthy adults during the menstrual cycle 
and healing wounds. Tumor growth beyond 2-3 mm and the development of mestastases are 
also angiogenesis dependent.1-3 Angiogenesis is a complex and highly co-ordinated process 
and thought to be regulated by an angiogenic balance, which essentially favors pro-angiogenic 
growth factors (stimulators) over anti-angiogenic growth factors (inhibitors). Locally 
activated stromal cells produce these angiogenic factors and recruited immune cells in wound 
healing. During tumor growth, tumor cells are an additional and a continuous source of 
angiogenic factor production. These angiogenic factors are also responsible for the 
recruitment of circulating endothelial progenitors (CEPs) from the bone marrow, which 
contribute to local angiogenesis in different amounts, depending on the demand and local 
situation. An impressive number of pro- and anti-angiogenic factors have been identified so 
far, which confirms the complexity of this process (Table 1). Besides angiogenic factors, a 
variety of proteases are also involved in angiogenesis. Among them, the family of 
metalloproteases (MMPs) and plasminogen activators (PAs) and their inhibitors are found to 
be important players in angiogenesis. Proteases facilitate the invasion and migration of 
endothelial cells (ECs), but by the very process of degradation of matrix proteins they may 
also generate protein fragments which have anti-angiogenic potential (e.g. endostatin). 
Finally, activated endothelial cells express a variety of adhesion proteins (integrins, 
cadherins), that are essential for the communication of endothelial cells with extracellular 
matrix proteins (ECMs). Together, this results in proliferation, migration and tube formation 
of endothelial cells. Maturation of these newly formed vessels is achieved by recruitment of 
smooth muscle cells (pericytes), which cover these vessels. In wound healing the acute 
generation of cell damage and local hypoxia and acidity initiates the process of wound 
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healing. Although the understanding of this complex process is growing, the fundamental 
aspects of wound healing have not been completely been characterized as yet.  
 
Table 1 
Pro-angiogenic factors Anti-angiogenic factors 
 
Vascular endothelial growth 
   factor (VEGF) 
Basic fibroblast growth  
   factor (bFGF) 
Platelet-derived endothelial cell 
   growth factor (PD-ECGF) 
Transforming growth factor 
   (TGF-α & β) 
Epidermal growth factor (EGF) 
Insulin-like growth factor (IGF) 
Hepatocyte growth factor/ 
    Scatter factor (HGF/SF) 
Granulocyte-macrophage 
colony growth factor (GM-CSF) 
Interleukins (IL-1, 4, 6, 8 & 15) 
Tumor Necrosis Factor-α (TNF-α) 
Angiogenin 
Angiotensin 
Angiotropin 
Fibrin 
Fibronectin 
Matrix metalloproteinases 
    
 
Endostatin 
Collagen IV fragments 
Angiostatin 
Thrombospondins (TSP-1 & 2) 
Tumor Necrosis Factor-α (TNF-α) 
Interleukins (IL-10, 12) 
Interferon (IFN-α, β and γ) 
Plasminogen activator inhibitors (PAIs) 
Tissue inhibitors of MMP (TIMP-1/-2) 
Transforming growth factor (TGF-β) 
Platelet Factor-4 
Thrombin Antithrombin Complex 
Soluble VEGF-receptor-1 
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THE THREE PHASES OF WOUND HEALING 
The wound healing process proceeds in three phases that overlap in time.  
These are:  1. Hemostasis and inflammation  
2. Proliferation and granulation  
3. Scar tissue remodeling.3  
Angiogenesis is an essential component in phase 1 and 2. 
Wound healing requires a complex control of biological events involving immunological and 
cellular reaction cascades, angiogenesis, production of extracellular matrix (ECM) proteins 
and cytokines.  
Cytokines are a large group of non-enzymatic proteins that sophisticatedly co-ordinate 
communications between target cells. Nearly all nucleated cells are capable of producing 
these proteins in response to intrinsic (autoimmunity) or extrinsic (infection) responses or 
wound healing. A common pathway in immune responses is the initial and immediate 
production of interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), followed after 6-12 
hours by interleukin-6 (IL-6) and interleukin-8 (IL-8). The local release of these cytokines 
will either directly or indirectly control the wound healing phases. It is the balance of various 
cytokines that play a pivotal role in regulating the initiation, progression and completion of 
wound healing. 
 
ANGIOGENIC CYTOKINES 
Cytokines that are associated with angiogenesis during wound healing are discussed here. 
IL-1 and TNF-α 
Both IL-1 and TNF-α level have been characterized by their quick systemic appearance and 
disappearance after surgery, due to their half-life in the circulation, which is respectively 6 
and 20 minutes.4,5 The primary sources of IL-1 after wounding are keratinocytes, 
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macrophages and endothelial cells, and TNF-α  is also released by keratinocytes, neutrophils, 
monocytes/macrophages and T-cells.6  
Both IL-1 and TNF-α are locally and systemically active. Abundant production of pro-
inflammatory cytokines from the local site of injury can be manifested systemically as fever, 
tachycardia, leucocytosis, and even shock and death.4  
A tempered and localized cytokine production is beneficial in the postoperative course of 
patients.  
Local IL-1 and TNF-α expression in wounds plays a role in immune response activation, such 
as neutrophil activation and proliferation of lymphocytes. In addition, these cytokines 
stimulate wound healing indirectly via fibroblast, immune cell activation, enhanced matrix 
turnover, and by their direct effects on endothelial cells.7-10 In vitro, in a dose dependent 
manner, TNF-α administration to endothelial cells causes structural changes and inter-
nucleosome cleavage of DNA associated with apoptosis in a concentration and time 
dependent manner.11 In vivo, TNF-α is a potent pro-angiogenic factor.9 TNF-α is significantly 
related to the vascular density index.12 An in vitro study suggested that TNF-α stimulated 
neutrophils resulting in increased release of intracellular stored vascular endothelial growth 
factor (VEGF), which is considered as one of the most potent angiogenic growth factors.13  
IL-6 
IL-6 is a pleiotrophic cytokine that can be expressed by various cells. The main sources in 
vivo are stimulated monocytes, fibroblasts, and endothelial cells.  
IL-6 is involved locally and systemically in modulation of host immune defense, such as 
activation of neutrophils and T-cells, and mediating the production of hepatic acute-phase 
proteins such as C-reactive protein, serum amyloid A, fibrinogen, α1-antitripsin, haptoglobin. 
In addition, IL 6 induces the expression of vascular endothelial growth factor in a variety of 
cells.14-16  
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The role of IL-6 in wound healing is still under investigation. Lin et al. conducted a wound 
study in IL-6-deficient mice and control mice. The IL-6-deficient mice had a delayed closure 
of the wounded area, with attenuated leukocyte infiltration, re-epithelialization, angiogenesis, 
and collagen deposition in contrast to the control mice. They suggested that IL-6 played a 
crucial role in wound healing, probably by regulating leukocyte infiltration, angiogenesis, and 
collagen accumulation.17  
Postoperative circulatory IL-6 levels have been found to correlate with the magnitude of the 
surgical trauma.16 Numerous studies have demonstrated convincingly lower systemic IL-6 
levels after minimal invasive or laparoscopic cholecystectomy than the open procedure.18,19  
In addition, IL-6 may be a predictor of postoperative complications.18 Pera et al. investigated 
the influence of postoperative inflammatory responses on angiogenesis and tumor growth. 
Mice with a coecum tumor were randomized into an open or laparoscopic cecectomy. They 
suggested that the increased systemic levels of  IL-6 and VEGF were associated with 
increased angiogenesis and tumor growth after open procedure when compared to 
laparoscopy. In addition, a positive correlation between IL-6 and VEGF postoperative serum 
levels was found.20  Of special interest are the IL-6 levels in wound fluid and peritoneal fluid 
after laparoscopic and conventional surgery, since the source for pro-inflammatory cytokines 
may be derived from cells accumulated in the wounded area. This may provide insight in 
wound healing caused by the two different surgical techniques. Several studies have 
investigated the concentration of pro-inflammatory cytokines locally (wound fluid) and 
systemically (blood) after laparotomy and mammoplasty and found that the cytokine levels in 
the wound were markedly higher than in blood. This may indicate compartmentalization, a 
local accumulation of these cytokines,21,22 which may be required for local host defense, 
angiogenesis and wound healing.  
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IL-8 
IL-8 is identified as a neutrophil and T-cell chemotactic factor.23,24 In addition, IL-8 is found 
to be a pro-angiogenic factor, inducing proliferation and chemotaxis of human umbilical vein 
endothelial cells.25 The fact that IL-8 does not bind directly to ECs suggests that the IL-8 
angiogenic effect is indirect.26 IL-8 is produced by neutrophils, monocytes and T-cells.27 Non-
hematological cells can also generate IL-8, e.g. keratinocytes, fibroblasts and endothelial 
cells, suggesting a role in wound healing.28 In vitro the effect of recombinant human IL-8 
(rhIL-8) resulted in significant keratinocyte proliferation and in vivo enhanced re-
epithelialization was observed in topically applied IL-8 on human split skin grafts in an 
experimental model.29 The postoperative IL-8 response is less frequently studied. Decker et 
al. demonstrated significantly higher plasma IL-8 level after open cholecystectomy when 
compared to minimal invasive surgery.30  
 
ANGIOGENIC GROWTH FACTORS INVOLVED IN WOUND HEALING 
A large number of pro-angiogenic and anti-angiogenic growth factors involved in 
angiogenesis have been found. Under normal conditions there is a tight physiological control 
of growth factors through a balance of pro-angiogenic and anti-angiogenic factors. Increased 
pro-angiogenic factors over anti-angiogenic factors results in angiogenesis. The most 
important pro- and anti-angiogenic factors, with emphasis on the ones, which have been 
investigated by us, are discussed here. 
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PRO-ANGIOGENIC FACTORS 
Vascular endothelial growth factor (VEGF) 
VEGF is a strong endothelial cell specific mitogen. Five VEGF ligands have been discovered, 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E. The most intensively explored is 
VEGF-A, which includes six isoforms, which are produced due to alternative RNA splicing, 
and contain 121, 145, 165, 189 and 206 amino acids.31 VEGF121 is completely soluble, 
whereas VEGF189 and VEGF206 bind to heparinsulphate glycoproteins (HSGPs) in the 
extracellular matrix (ECM) and are mainly responsible for VEGF gradients, which direct 
endothelial cell migration to the sources of VEGF production. 
Sofar three high affinity receptors have been identified VEGFR-1 or Fms-like tyrosine kinase 
(Flt-1), and VEGFR-2 or kinase domain receptor (KDR/Flk-1) are mainly localized on 
vascular endothelial cells. VEGFR-1 participates in cell migration, while VEGFR-2 is 
responsible for mitogenic signaling and is considered to be the main regulator of tumor 
angiogenesis. VEGF-C and VEGF-D are ligands for VEGFR-3, which is expressed on 
lymphatic endothelial cells in adults. Neuropilin-1 (VEGF-4) binds selectively with VEGF165 
and co-ordinates neuronal and vascular development.31-34   
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Figure 1. Receptors for VEGF and related ligands include: VEGF R1 (Flt-1), VEGF R2 
(KDR/Flk-1), VEGF R3 (Flt-4), Neuropilin-1, and Neuropilin-2. The interaction of heparin-
binding forms of VEGF with heparan sulfate may assist in presentation to VEGF receptors. 
Note: The figure is provided by R&D Systems, Vascular Endothelial Growth Factor (VEGF), 
in R&D Systems 2000 Catalog. 
 
VEGF production is up-regulated by a wide array of factors, including hypoxia (by 
stabilization of the transcription factor hypoxia inducible factor 1α (HIF-1α)), hypoglycemia, 
mutations of oncogenes (Ras, Raf, Src) and suppressor genes (p53), cytokines such as IL-1, 
IL-6, TNF-α, insulin-like growth factor (IGF-1), transforming growth factor (TGF-α and-β), 
and basic fibroblast growth factor (bFGF). VEGF is released by a variety of hematological 
cells, such as platelets, neutrophils, macrophages, T- and B-lymphocytes, as well as non-
hematological cells, such as keratinocytes, hepatocytes and almost every type of tumor 
cells.31,35-41 Elevated tumor or circulating VEGF levels are predictive of poor survival for 
many solid tumors, and are associated with enhanced microvessel density in tumor tissue.42-47 
Raised VEGF levels in cancer patients are contributed to tumor cell harboring specific genetic 
alterations leading to VEGF overproduction. Coagulation abnormalities and increased 
platelets turnover are also frequently found in patients with cancer. Verheul et al. 
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demonstrated that the occurrence of platelet adhesion and activation within the tumor may be 
induced by VEGF activated ECs. This implicates that intratumoral trapping of platelets may 
be responsible for raised platelet turnover in cancer patients.48 The discussion whether plasma 
or serum VEGF levels should be used is still ongoing. Lee et al. suggested that platelets 
facilitate the process of tumor metastasis by forming aggregates with circulating tumor cells. 
For this reason, they advocate the usage of serum VEGF in the diagnosis and follow-up of 
cancer.49  Coagulation during the processing of serum induces platelet degranulation and 
subsequent release of stored VEGF.48 The processing of plasma is not dealing with platelet 
spillover of VEGF and may therefore represent the actual circulating VEGF concentration, 
which is about four times lower than in serum. 
Raised circulating VEGF levels have been identified after surgery50,51 which may be 
generated by local platelet degranulation, recruited leucocytes that are involved in the repair 
of injured tissue, by cells activated by hypoxia in devitalized tissue and by up-regulation of 
IL-6 and several growth factors.16,40,41,52,53 When systemic VEGF levels is compared to local 
VEGF values a large difference is found. It appears that the circulatory VEGF reflects only a 
fragment of what is generated in wound fluid.54  
This observation was supported by Hormbrey et al. who describe the VEGF production in 
human surgical wounds and the systemic VEGF level changes in patients undergoing benign 
breast or breast cancer surgery. They suggested that the small blood changes compared with 
the abundant wound fluid VEGF levels show that there is a tissue barrier.55  
The local VEGF production is thought to initiate wound angiogenesis, restore the route for 
oxygen and nutrient delivery and removal of waste products. It induces vascular permeability 
resulting in deposition of plasma proteins in the wounds or tumor environment. These 
proteins (fibrin, e.g.) form a provisional matrix, which strongly stimulates the proliferation 
and migration of endothelial cells. VEGF stimulates granulation tissue formation56 and has an 
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anti-apoptotic effect on EC,57 which may be crucial for survival of ECs during wound healing. 
In addition, it may be speculated that local VEGF is a physiological immunosuppressive agent 
in the injured area. Injured tissue contains devitalized tissue and exposed self-antigens that are 
physiologically controlled by immunosuppressive factors present within the wound.58 VEGF 
inhibits the maturation and activation of dendritic cells and may act as an immunosuppressive 
agent that prevents a local autoimmune reaction. Cancer cells may use the 
immunosuppressive capacity of VEGF for immunological tumor escape.59-61 
In summary, the local generation of VEGF is of great importance for wound healing, however 
VEGF may also have stimulating effects on tumor cells that are left or disseminated in a 
wound. 
 
Fibroblast growth factor (FGF) 
Two forms of FGF, acidic FGF (aFGF or FGF-1) and basic FGF (bFGF or FGF-2) have been 
identified. This review is restricted to bFGF.  
Basic FGF is a growth factor present in normal tissues as well as in tumors. It is a heparin 
binding polypeptide with several isoforms ranging from 18 to 24 kDa.62 Basic FGF induces 
angiogenesis both in vitro and in vivo.63,64 
Endothelial cells, granulocytes and platelets contain large amounts of this factor.62-68 Locally 
generated bFGF is bound to FGF-receptors in the basement membrane and ECM, where it can 
be released by ECM-degrading enzymes.69-70 Wounding as well as degradation of the ECM by 
invasive tumors may release sequestered bFGF hereby stimulating wound healing, but also 
tumor growth and angiogenesis.71,72 The prognostic impact of bFGF is still inconclusive. 
Several authors demonstrated significant association between tumors expressing bFGF and 
poor prognosis72-75 and others did not find such a correlation.76-78 
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ANTI-ANGIOGENIC FACTORS 
Several endogenous angiogenic inhibitors have been identified. They may be down regulated 
during tumor growth or overpowered by the abundance of pro-angiogenic factors. The 
physiological function of angiogenic inhibitors in wound healing is unclear, but, as it is a 
physiological process with an initiating and a stopping phase, one might expect that these 
factors may decrease in the first and reappear in the end phase of wound healing. 
 
Angiostatin 
Angiostatin is a 38 kDa internal fragment of plasminogen. Enzymatic digestion of 
plasminogen by matrix metalloproteinases (MMPs) and plasminogen activators (PAs), such as 
tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), lead to the 
formation of angiostatin. MMP members such as stromelysin-1 (MMP-3), matrilysin (MMP-
7), gelatinase/typeIV collagenase (MMP-9) and macrophage-derived metalloelastase (MMP-
12) have been implicated in the in vitro production of angiostatin.79-83 Angiostatin containing 
kringle 1-5, K1-4 or K1-3 have angiogenesis suppressing activity.84-86  
O’Reilly et al. demonstrated in an experimental study that a primary tumor could suppress its 
own micrometastases through production of angiostatin. Surgical excision of that primary 
tumor removes the production source of angiostatin, which can result in permissive outgrowth 
of previously dormant micrometastases.87 
In our study patients undergoing colorectal carcinoma surgery two types of angiostatin 
(kringle 1-3 and kringle 1-4) became visible postoperatively.88 The postoperative angiostatin 
expression is interesting. An in vitro study has shown that upon stimulation with a pro-
inflammatory stimulus, human PMN release enzymatic activities that generate bioactive 
angiostatin fragments from plasminogen.89  
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It is also conceivable that the same proteolytic enzymes, involved in early stages of wound 
healing are involved in the conversion of plasminogen into the angiostatin isoforms.90  
This role of postoperative circulatory angiostatin expression is unclear. It may prevent 
postoperative vessel sprouting outside the wounded area, by functioning as a systemic 
homeostatic control, counterbalancing spilled-over circulatory pro-angiogenic factors such as 
VEGF. 
 
Endostatin 
Endostatin is produced from the C-terminal fragment of collagen XVIII by enzymatic 
digestion. In vitro generation of endostatin by elastase and cathepsin L has been 
demonstrated.91,92 Collagen XVIII has been shown to reside in basement membranes. 
Hepatocytes are a major source of collagen XVIII and may contribute to circulating 
endostatin levels.93,94 Circulating endostatin values are detectable in both healthy controls as 
well in cancer patients.95 It is suggested that endostatin measured in the circulation of healthy 
volunteers may serve as an angiogenic homeostatic surveillance, controlling undesired vessel 
outgrowth. Endostatin may temper circulatory VEGF, also detectable in healthy individuals. 
Hajitou et al. demonstrated in a mouse aortic ring model a down-regulation of VEGF mRNA 
expression in endostatin-treated rings. A similar down-regulation of VEGF expression at both 
mRNA and protein levels in tumor cells was also shown in in vivo cancer models after 
treatment with endostatin and angiostatin.96 Treatment with endostatin decreased also the 
levels of progenitors of endothelial cells in the circulation in vivo.97 Higher endostatin levels 
have been detected in some cancer patients,98,99 suggesting that primary tumors generate 
proteases able to properly cleave collagen XVIII present in the direct environment.100 It is 
unclear whether tumor-derived endostatin, just as angiostatin, is effective in inhibiting its own 
metastases. The systemic and local endostatin level after a surgical trauma and subsequent 
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wound healing is interesting. We observed a significant decrease of both systemic and local 
endostatin levels in patients undergoing benign or cancer surgery.54,88,101 The precise 
mechanism of the decrease of endostatin levels is unclear. It may be caused by the expression 
of various proteolytic enzymes during wound healing resulting in the degradation of 
endostatin. Alternatively, Wu et al. demonstrated in an in vitro study that ECs and pericytes 
are able to generate endostatin, which decreased under hypoxic conditions. These results 
suggest that the reduction of autocrine endostatin is an important aspect of hypoxia-driven 
angiogenesis.102  
Bloch at al. demonstrated that exogenously administered endostatin impaired blood vessel 
maturation in mice with excisional wounds on their back.103 
Treatment with endostatin has shown to inhibit endothelial cell migration in vitro, as well as 
tumor growth in in vivo studies.104-107  The precise mechanisms of endostatins anti-angiogenic 
activity are complex, with highly interactive angiogenic signaling network (Figure 2).108 It has 
been shown that endostatin binds to α5β1 integrin resulting in inhibition of EC migration.109 
Further binding to specific isoforms of tropomyocin in endothelial cells is suggested, leading 
to a disruption of microfilament integrity and inhibition of cell motility, the promotion of 
apoptosis by suppressing bcl-2 and the induction of endothelial cell cycle arrest by down-
regulating the cyclin D1 promoter in vitro.110-113 A recent study suggested in an in vitro study 
that endostatin predominantly causes autophagic cell death in human endothelial cells through 
an oxidative-independent pathway, which is regulated by serine and cysteine lysosomal 
proteases.114 
Together, the recent evidence concerning the mechanisms of action of endostatin suggests that 
it brings about an orchestrated anti-angiogenic response by up-regulating a number of 
essential angiogenesis inhibitors and down-regulating the expression of important 
angiogenesis stimulators.108 
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Figure 2. Endostatin Signaling Network 
Integration of endostatin signaling network in endothelial cells with emphasis on the 
downregulation of proangiogenic pathways. Effects of endostatin include the RNA 
downregulation of key pathways involved in angiogenesis such as Ids, HIF1-α, Ephrins, NF-
κB, AP-1 (and MAPK), Stats, Ets, and thrombinreceptors (the coagulation cascade) (orange 
ovals). The orange ovals represent major pathways that we focused on because of their ability 
to regulate several genes and their importance for elucidation of the network. Upstream and 
downstream of these key regulatory elements, endostatin downregulates a cascade of 
interdependent genes including genes of the VEGF family, Bcl-2, LDH-A, MMPs, TNF-α, 
COX-2, αVβ3 (blue ovals). In addition, endostatin also dephosphorylates many proteins 
involved in angiogenic cell signaling including Id1, JNK, NF-κB, or Bcl-2 (small circle P-) or 
phosphorylates proteins such as cyclin D (small circle P+). This network of inter-pathway 
communications shows that endostatin influences a large number of signaling pathways 
involved in angiogenesis. [Note the illustration and figure are adapted with permission from 
A. Abdollahi. Endostatin's Antiangiogenic Signaling Network. Mol Cell. 2004;13:649-63]. 
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WOUND HEALING PROCESS 
We mentioned three wound healing phases: hemostasis and inflammation, proliferation and 
granulation, and scar formation, overlap in time. In these three phases different cells play an 
eminent role. 
 
PHASE 1: HEMOSTASIS AND INFLAMMATION  
Platelets 
Injury and the accompanying vessel rupture exposes subendothelial collagen to platelets, 
resulting in platelet sequestration, degranulation and initiating the clotting cascade. Growth 
factors such as platelet derived growth factor (PDGF), insulin-like growth factor-I (IGF- I), 
transforming growth factor (TGF-β), bFGF and VEGF are stored within the α-granules of 
platelets and are released upon platelet degranulation. Simultaneously, the clotting cascade is 
initiated consisting of the intrinsic and the extrinsic system. The intrinsic factor is activated by 
Hageman factor (factor XII) when contact is made between blood and exposed endothelial 
cell surfaces. The extrinsic factor is initiated by exposure of tissue factor, which is released by 
tissue damage. The two pathways converge into the final common pathway leading to the 
formation of fibrin, anaphylatoxins, and the complement factors, C5a and C3a. The formed 
plug consists of platelets trapped in fibrin fibers, which serve as a temporary cytokine 
reservoir.115  
This first wave of cytokines, consisting of growth and chemotactic factors, initiates the wound 
healing process and recruitment of inflammatory cells. 
The degranulation of platelets releasing a first wave of growth factors suggests that platelets 
are important in the wound healing process. Szpaderska et al. however, could not confirm this 
idea. They obtained full-thickness excisional dermal wounds from normal and 
thrombocytopenic mice. The thrombocytopenic mice exhibited no delay in the reparative 
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aspects of wound healing and the rate of wound re-epithelialization, and collagen synthesis 
and angiogenesis was nearly identical when compared to control mice. They suggest that 
platelets do not significantly affect the proliferative aspects of repair, including wound 
closure, angiogenesis, and collagen synthesis.116  
 
Neutrophils 
The neutrophils are the first nucleated cell to arrive in minutes to hours by leaving the 
circulation via endothelial cell transmigration to the site of injury (Figure 3). The migration is 
promoted by increased vascular permeability and the release of chemotactic substances such 
as IL-1, IL-6, TGF-β, platelet factor 4 (PF-4) and complement factors. The neutrophils adhere 
to the endothelium by selectins on the endothelial cell surface.117 Further migration into the 
ECM occurs by expressing integrin receptors on the neutrophil cell surfaces.118 
Activated neutrophils release free oxygen radicals and lysosomal enzyms, which cleanse the 
injured area from foreign particles. Neutrophils have been mainly considered to be involved 
in infection control and their contribution to the wound healing process is thought to be 
minimal.119 McCourt et al. showed that human neutrophils activated by LPS and TNF-α 
release VEGF, resulting in stimulation of endothelial cell proliferation and tube formation.13  
In contrary, an in vitro study suggested that activated neutrophils by a pro-inflammatory 
stimuli, generate bioactive angiostatin fragments from purified plasminogen.89  
A recent study investigated the wound healing process in neutrophil-depleted mice. The 
epidermal healing, measured by wound closure, proceeded significantly faster in neutropenic 
than control mice. However, neutrophil depletion did not affect dermal healing, collagen 
deposition and wound-breaking strength was significantly different between neutropenic and 
control mice.120  
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In conclusion, neutrophils typically provide a first line defense against infections. In addition, 
activated neutrophils may also produce a number of growth factors that appear to have 
stimulatory or inhibitory effect on the angiogenic process. 
 
Macrophages 
Macrophages replace the neutrophils in the wound by the third or fourth day. When 
monocytes leave the vascular system they will adhere to the extracellular matrix and undergo 
metamorphosis into inflammatory or reparative macrophages. The differentiation of 
macrophages is mediated by specific cytokines, such as granulocyte-macrophage colony-
stimulating factor (GM-CSF), TNF-α, and IL-4.121  
Reduced vascular perfusion in tissues generates tissue ischemia and a marked reduction in 
local levels of oxygen and glucose may stimulate macrophages to express pro-angiogenic 
factors in wounds.122  
Constant et al. investigated the effects of hypoxia, lactate on the expression of vascular 
endothelial growth factor by cultured macrophages. A significantly increased level of VEGF 
mRNA and VEGF protein in the conditioned media was found.123 The wounds of animals 
depleted of macrophages healed poorly.124  
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Figure 3. Wound healing is a complex process encompassing a number of overlapping 
phases, including inflammation, epithelialisation, angiogenesis and matrix deposition. During  
inflammation, the formation of a blood clot re-establishes hemostasis and provides a  
provisional matrix for cell migration. Cytokines play an important role in the evolution of  
granulation tissue through recruitment of inflammatory leukocytes and stimulation of  
fibroblasts and epithelial cells. [Note the illustrations are provided courtesy of R&D Systems, 
Inc. Cytokine Bulletin, Winter 2001. The figure is adapted from Singer, A.J. and R.A.F Clark 
(1999) "Cutaneous Wound Healing" The New England Journal of Medicine 341:738-746].  
 
 
Epithelialization 
Within hours after wounding, the epithelial cells start loosening cell-cell and cell-matrix 
contacts and migration occurs on the collagen-fibronectin wound surface. Local release of 
growth factors, loss of contact inhibition and exposure to fibronectin stimulate migration and 
proliferation until the epidermis reaches its appropriate thickness.  
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PHASE 2: PROLIFERATION AND GRANULATION  
Granulation tissue developing from the connective tissue surrounding the damaged area is a 
provisional matrix for inflammatory cells, ECs, fibroblasts and myofibroblasts. In the wound 
platelets and fibroblasts synthesize this provisional matrix. The constituents of granulation 
tissue include fibrin, fibronectin, and hyalounouric acid. VEGF is a key factor in this process, 
highlighted by the fact that when neutralizing antibodies experimentally inactivate VEGF, a 
near complete absence of granulation tissue was observed.56 
Chemotactic factors and growth factors, such as TGF-β, which are derived from activated 
macrophages and platelets in the wound, provide a cytokine concentration gradient that 
coordinates the migration of endothelial cells and fibroblasts. Fibroblasts migrate into the 
wound site from the surrounding mesodermal elements on the third day after wounding and 
peak at day seven.3  
An acellular collagenous matrix gradually replaces the provisional matrix and the production 
stimulus stops by not well defined signals. Most probably the disappearance of activated cells, 
the normalization of oxygen tension and the restoration of the angiogenic balance contribute 
to these stopping signals. 
TGF-β has been shown to be the most important growth factor for the differentiation of 
fibroblasts to contractile wound myofibroblasts,125 which is required for wound closure.  
 
Angiogenesis 
The series of events leading to new vessel growth is complex. Angiogenesis is already 
initiated minutes after wounding and during wound healing phase tube formation is completed 
(Figure 4). Local acidosis, hypoxia due to tissue and vessel destruction and local induction of 
pro-angiogenic factors attribute to the initiation of angiogenesis.  
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The activation of previously quiescent ECs results in proliferation and migration. 
Simultaneously, proteolytic enzymes, such as serine proteases (urokinase-type plasminogen 
activator (uPA) and tissue-type PA (tPA)) and matrix metalloproteinases (MMPs) are released 
to degrade the ECM allowing EC migration towards the angiogenic source.126 Angiogenesis 
ceases once the wound is filled with new granulation tissue and most new vessels will 
disintegrate as a result of apoptosis.127 This endothelial program cell death may be regulated 
by thrombospondin 1 and 2, angiostatin and endostatin and by the decline in VEGF 
production.128 
 
Figure 4. The remodeling phase (i.e. re-epithelialization and neovascularization) of wound 
healing is also cytokine-mediated. Degradation of fibrillar collagen and other matrix proteins 
is driven by serine proteases and MMPs under the control of the cytokine network. 
Granulation tissue forms below the epithelium and is composed of inflammatory cells, 
fibroblasts and newly formed and forming vessels. [Note the illustrations are provided 
courtesy of R&D Systems, Inc. Cytokine Bulletin, Winter 2001 The figure is adapted from 
Singer, A.J. and R.A.F Clark (1999) "Cutaneous Wound Healing" The New England Journal 
of Medicine 341:738-746].  
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PHASE 3: SCAR TISSUE REMODDELING 
Collagen remodeling to scar formation is a dynamic process. Clinically this is the most 
important phase of healing since the rate, quality and quantity of matrix deposition determines 
the strength of the scar. Despite the increase in wound strength, the healed wound is at 70% 
maximum strength when compared to uninjured skin.  
 
WOUND FLUID 
Wound fluid is an exudate composed of cell lysate and products secreted by different cells. 
Wound fluid is believed to reflect the local wound environment and represents the sum of all 
local specific activities at the time of harvest. Various quantitative cytokine analysis studies in 
wound fluid, peritoneal fluid and serum indicated that the local cytokine production is much 
higher than found in the circulation.129-131 Functional analysis of wound fluid suggested that 
wound fluid taken in the early healing stages increased the proliferation of fibroblasts and EC, 
whereas fluid taken from later wound healing phases (day 15) decreased the proliferation of 
these cells.132-134 Wound fluid stimulates the synthesis of collagen.133-134 
Very limited clinical studies have focused on the pro-and anti-angiogenic balance in wound 
fluid and in the circulation of patients, who underwent surgery because of cancer or other 
reasons. 
 
SURGERY AND WOUND HEALING 
Tumor cells shedded in the circulation during oncologic surgery have been detected135,136  and 
are of main concern. Dormant micrometastasis are biologically active with a rate of cell 
proliferation equal to the rate of apoptosis, with no net growth of the metastasis as a result.137 
The pro-angiogenic environment during wound healing may contribute to the genesis of 
recurrent disease, locally and at distance.  
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In 1860 Virchow’s studies implied that inflammation during wound healing could function as 
an initiator of tumor growth. This early concept has been confirmed by current experimental 
studies that tumors specifically developed in injured tissue and as the wound healed their 
ability to grow and implant decreased.138 Bogden et al. demonstrated that surgical wounding 
of normal tissues significantly stimulated tumor growth at distance.139 Recently it was 
demonstrated that pro-angiogenic factors which are generated during wound healing are also 
involved in the outgrowth of tumors.140 An immediate increase of circulating VEGF in 
patients after pulmonary metastasis resection was observed and it has been shown 
experimentally that VEGF administration resulted in rapid outgrowth of micrometastases. 
This outgrowth was abolished by an anti-angiogenesis treatment.51  
In addition, an intact primary tumor can regulate growth of micrometastasis through 
production of anti-angiogenic factors, notably angiostatin and endostatin. Surgical removal of 
a primary tumor removes the sources of these inhibitors, and might allow growth of 
previously dormant micrometastases.87 This observation has only been demonstrated in 
animal models but may well exist in humans.  
Angiogenesis blocking strategies make use of a wide array of direct, EC targeting, and 
indirect, influencing the EC microenvironment, anti-angiogenesis agents. Various 
experimental and clinical anti-angiogenic trials are focused on sustaining perpetual 
micrometastases in dormancy.104,141-145 The use of postoperative anti-angiogenic agents in 
surgical cancer patients is tempting in order to control the excessive production of pro-
angiogenic growth factors, which are generated as a physiological response in the early 
postoperative period. However, these clinical studies are limited, mostly due to an 
understandable fear of impaired angiogenesis during wound healing.  
Roman et al. administered perioperatively the antiangiogenic agent SU5416, an inhibitor of 
signaling via the VEGFR, in an experimental placebo controlled study in which he performed 
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a right pulmonary lobectomy and biopsies. Interestingly no gross effect on wound healing in 
treatment groups was observed. In addition, no drug-related impairment of histologic healing 
or decrease in wound tensile strength was demonstrated.146  
Another experimental study evaluated the effect of postoperative continuous or discontinuous 
angiostatin treatment on the healing of colonic anastomoses. They suggested that the 
anastomotic healing was impaired when angiostatin was continuously administered, whereas 
normal colonic healing was restored when the anti-angiogenic agent was preoperative 
discontinued.147     
In conclusion, anti-angiogenic therapy combined with surgical treatment may be a future 
strategy for induction of remission by maintaining tumor cells dormant. However, the timing 
of anti-angiogenic administration is essential, as wound healing (skin, bowel anastomoses, 
and liver regeneration) may be impaired by anti-angiogenic agents. 
 
SCOPE OF THE THESIS 
This thesis is divided in three parts and addresses the peri-operative angiogenic balance 
between stimulators and inhibitors of the wound healing process.  
 
PART I 
A common pathway in response to trauma is initiated first by interleukin-1 (IL-1) and tumor 
necrosis factor-α (TNF-α), followed by interleukin-6 (IL-6) and interleukin-8 (IL-8). This 
consequently recruits immune cells required for host defense and wound healing. 
The aims of Chapter 2 were to study the generation of some important pro-inflammatory 
cytokines in wound fluid and in the circulation after conventional and minimal invasive 
surgery in patients with a primary colon carcinoma. In addition, the systemic immune 
responses after both procedures are investigated. 
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PART II 
 
Cancers generate VEGF, which may accumulate in their direct environment and increase in 
the circulation. Therefore, we first wanted to study the effect of surgery on the angiogenic 
balance in non-cancerous patients in which minimal invasive versus conventional surgery was 
performed. 
The aim of Chapter 3 was to investigate the effect of the extent of operative trauma of 
patients without cancer (laparoscopic versus conventional Nissen fundoplication) on the 
angiogenic balance of VEGF and endostatin in plasma.  
In Chapter 4 we examined the VEGF and endostatin profile in wound fluid and blood of 
patients undergoing breast surgery. Two patient groups were compared, group I had a breast 
carcinoma and group II were female-to-male transsexuals undergoing mastectomy.  
In Chapter 5 local and systemic angiogenic changes of VEGF and endostatin in patients 
undergoing laparoscopic or open surgery for colon cancer were investigated. 
 
PART III 
 
Peri-operative immune therapy is a valuable option to avoid postoperative infections. Various 
studies have investigated the immunomodulatory response of a wide array of cytokines. These 
cytokines have anti- (interferon, e.g.) or pro-angiogenic potential, but the effect on 
angiogenesis has not been studied extensively. RhGM-CSF has been widely used to stimulate 
the immune system. In addition, it has been suggested that rhGM-CSF affects the process of 
angiogenesis via multiple pathways. The aim of Chapter 6 was to investigate the effects of 
surgery with or without rhGM-CSF on angiogenic parameters, notably VEGF, endostatin and 
angiostatin, in patients with a colorectal carcinoma. 
Perioperative recombinant bactericidal/permeability-increasing protein (rBPI21) 
administration in patients undergoing liver surgery resulted in a reduced incidence of 
postoperative infectious complications. Recently it was demonstrated that rBPI21 had also 
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anti-angiogenic capacity. Chapter 7 is a double blind randomized controlled study in which 
patients with metastasized colorectal carcinoma were enrolled to investigate the effect of liver 
surgery, with perioperative rBPI21 or placebo administration, on circulatory angiogenic 
cytokines. 
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ABSTRACT 
Purpose: This study is to evaluate differences in both the peritoneal and systemic 
immune response following laparoscopic and conventional surgical approaches.  
Methods: Patients with a primary carcinoma were prospectively randomized to 
curative laparoscopic (n = 12) or conventional (n = 14) colon resection. Pro-inflammatory 
cytokines interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) were 
measured in the peritoneal drain fluid and in the serum. C-reactive protein (CRP) and 
leucocyte counts as well as the differences in leucocyte subpopulations and expression of 
human leucocyte antigen-DR (HLA-DR) on monocytes were measured perioperatively.  
Results: Significantly higher pro-inflammatory cytokine levels are found in the 
peritoneal drain fluid than in the circulation after both procedures. Serum IL-6 and IL-8 levels 
were significantly lower 2 hours after laparoscopic surgery compared to the conventional 
procedure. Postoperative cellular immune counts and HLA-DR expression normalized earlier 
after the laparoscopic approach.  
Conclusions: The systemic pro-inflammatory concentrations after both surgical 
approaches represent only a small fragment of what is generated in the peritoneal drain fluid. 
Even if the immediate pro-inflammatory cytokines in the serum are significantly lower in the 
laparoscopic group, the same cytokines locally produced showed no differences, suggesting 
that both intra-abdominal approaches are equally traumatic. No differences in cellular 
response between the two groups were observed. 
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INTRODUCTION 
Surgery, whether conventional (CO) or laparoscopic (LP), is a controlled trauma with 
immunologic consequences. The extent and duration of the postoperative immune suppression 
depends on the magnitude and type of the intraoperative injury.1 Postoperative immune 
suppression may have considerable consequences as it has been related to infectious 
complications and the development of tumor metastases in animal studies.2,3 Some clinical 
research has focused on the prevention or reversal of this immune suppressive state, by 
modulating the operative trauma or by administration of different growth factors, in order to 
reduce postoperative morbidity and gain a better prognosis. 
In comparing laparoscopic versus conventional surgery, significantly better protection of the 
systemic immune system was shown with laparoscopic cholecystectomy and Nissen 
fundoplication than with the conventional approach.4-6 The differences between laparoscopic 
and conventional colectomy are less convincing. Laparoscopic resection of colorectal cancer 
has not gained universal acceptance, because of the fear of port-site metastasis and the fact 
that the immunologic advantage of laparoscopy remains controversial in clinical trials and 
limited prospective, randomized trials.7-12 To understand the differences between these two 
approaches, systemic but also locally inflammatory and immunologic parameters will add 
information important to the final clinical outcome. 
Circulating pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis 
factor-α (TNF-α) have been related to the extent and severity of the surgical procedure.13 The 
main source for these circulating pro-inflammatory cytokines is largely derived from the 
operative area. Systemic as well as local measurement in peritoneal wound fluid (PDF) of 
these cytokines may provide insight into the differences of operative trauma here considered. 
To our knowledge, this has not yet been evaluated in this context.  
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To assess the preservation of the postoperative immunologic defenses, the expression of 
human leukocyte antigen-DR (HLA-DR) on monocytes proved to be a reliable parameter,14 
since HLA-DR molecules are a prerequisite for effective antigen presentation and play an 
important role in the immune response.14 
In this prospective, randomized study, the systemic and local acute inflammatory responses as 
well as the immunologic consequences of both surgical procedures have been evaluated. The 
primary endpoints of the study were to demonstrate differences in both local and systemic 
immune parameters by evaluating pro-inflammatory cytokines (IL-6, interleukin-8 (IL-8), 
TNF-α, and C-reactive protein (CRP)), leukocyte counts, and the differences in leukocyte 
subpopulations and HLA-DR expression after laparoscopic and conventional colon resection 
for cancer. 
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STUDY DESIGN 
Twenty-six patients were enrolled as part of the international multi-center COLOR (colon 
cancer laparoscopic or open resection) trial. In this prospective, randomized study, patients 
were randomly allocated a computer-generated number, which assigned them to undergo 
either a laparoscopic, or conventional curative colon carcinoma resection. The Ethics 
Committee of the VU Medical Center, Amsterdam approved this protocol. Informed consent 
was obtained from all patients. The inclusion and exclusion criteria are according COLOR 
trial. 
Peripheral heparinized plasma and serum plain tube samples (7 ml Vacutainer Systems 
Europe, Becton Dickinson, from Meylan Cedex France and Plymouth UK, respectively) were 
collected preoperatively (baseline), 2 hours, 1 day and 4 days after surgery. A low vacuum 
abdovac drainage system (Astra, Rijswijk, the Netherlands) was left at the resection site for 
peritoneal fluid drainage. Twenty-four-hour peritoneal fluid production was collected on days 
1 and 4. Serum and wound fluid IL-6, IL-8 and TNF-α samples were obtained by 
centrifugation for 10 minutes at 3,000 rpm at 40C. All samples were stored in aliquots at  
–800C until tested. 
 
Phenotyping of Immune Cells 
The following immune parameters were determined in fresh (<6h) heparinized venous blood 
after erythrocyte lysis and paraformaldehyde fixation of whole blood samples (Q-prep, the 
Coulter Corporation, Miami, FL, USA): the absolute numbers of leucocytes, total lymphocyte 
count, the counts of monocytes (CD14+), T-helper lymphocytes (CD4+), T-suppressor 
lymphocytes (CD8+), B-lymphocytes (CD19+), natural killer (NK) cells (CD3neg, 
CD16/56pos) and the counts of NK-like T-cells (CD3neg, CD16/56pos). In addition, HLA-
DR expression on CD14+ cells was evaluated by FACS analysis (FACStar Plus, Becton 
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Dickinson, San Jose, CA, USA) and expressed as the ratio of fluorescence intensity (mean 
fluorescence and peak channel) with and without anti-HLA-DR-FITC. All monoclonal 
antibodies were purchased from Becton Dickinson, San Jose USA and used for overnight 
staining (each cell pellet with 20 :l 10-fold diluted Moabs or 30-fold diluted anti-HLA-DR, at 
4oC in the dark). 
 
Interleukin-6, and -8 and Tumor Necrosis Factor-α 
IL-6, IL-8 and TNF-α concentrations in serum and PDF were measured using commercially 
available enzyme-linked immunosorbent assay kit (Pelikin compact human IL-6, IL-8 and 
TNF-α ELISA kits, CLB, Amsterdam, the Netherlands). 
 
C-Reactive protein (CRP) 
Plasma CRP levels were measured by the immunoturbidimetric method, using the 
BM/Hitachi 705 (Boeringher, Mannheim, Germany). 
 
STATISTICAL ANALYSIS 
The results are reported as mean ± standard error of the mean (SEM). The “Statistical 
Package for the Social Sciences” (SPSS 7.5 tm) was used to analyze the data. Overall 
differences between groups were analyzed by means of a two-way analysis of variance, and if 
a significant overall difference between groups was found, the two-sample Mann-Whitney U 
test was used. The Wilcoxon Signed Ranks Test for two related samples analyzed differences 
within groups. Significance was accepted at a two-tailed P<0.05. 
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RESULTS 
The demographic data are shown in Table 1. 
The average hospital stay for the laparoscopic group was shorter than in the conventional 
group, P=0.02. On the first postoperative day after conventional sigmoidectomy, one patient 
required relaparotomy because of hemorrhaging. One patient who had a laparoscopic right 
colectomy had a wound abscess that resolved after draining. 
 
 Laparoscopy Conventional 
No. Patients   12   14 
 
Sex (M/F)   2/10   8/6 
 
Age (yr)   66 ± 3  69 ± 2 
 
Astler-Coller (A:B:C) 
Males 
Females 
Hemicolectomy right 
Sigmoid resection 
 
 0:2:0 
 0:0:10 
  6 
  6 
 
 0:7:1 
 0:3:3 
  8 
  6 
 
Operative time 
(minutes) 
176 ± 15 143 ± 9 
 
 
Hospital stay 
(days) 
 
   9 ± 0.5#   12 ± 1 
Table 1:  Demographic data  
                Mean ± SEM 
                # P < 0.05, laparoscopy versus conventional 
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Pro-inflammatory cytokines 
Serum IL-6, TNF-α, IL-8 and CRP plasma levels were measured in 12 laparoscopic and 14 
conventional patients. In addition, the local production of IL-6, IL-8 and TNF-α was 
evaluated in wound fluid. Tables 2 & 3 summarizes PDF and serum levels of respectively  
IL-6 and IL-8 matched for five laparoscopic and eleven conventional patients.  
Circulating IL-6 and IL-8 are depicted in figures 1 and 2, respectively. In the conventional 
group, the serum IL-6 level was highest at two hours postoperatively (P=0.01) and was still 
elevated at day +1 (P=0.001), as compared to baseline values. In the laparoscopic group, 
increased IL-6 levels were found 2 hours postoperatively (P=0.03) and were highest at day +1 
(P=0.01) as compared to baseline values. Between the groups, IL-6 levels were lower in the 
laparoscopic group than in the conventional procedure (P=0.04) two hours after surgery.  
The IL-6 levels were much higher in the PDF than in the serum. Remarkably, serum levels of 
IL-6 dropped at day +4 despite a continuing increase in local production. In the laparoscopic 
group, PDF IL-6 concentrations were not significantly lower than in the conventionally 
operated patients at day +1 and day +4, respectively P=0.257 and P=0.610. In addition, serum 
IL-6 levels did not differ between the two groups at these time points. 
All TNF-α levels in both groups were below the detectable level, < 25 pg/ml in the serum and 
< 12 pg/ml in the PDF at all time-intervals. 
Similar to IL-6 levels, IL-8 serum levels were significantly lower in the laparoscopic group  
2 hours after operating (P = 0.03), whereas no differences were found at day +1 and day +4. 
Local production, expressed as the PDF IL-8 concentration, was much higher than serum IL-8 
levels. As shown in Table 3, no differences were found in local IL-8 production between 
laparoscopic and conventional surgery, although PDF levels P=0.04 tended to be higher in the 
laparoscopic group at day +4.  
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Figure 1: IL-6 levels in mean ± SEM  
 
                 * P < 0.05, postoperative values compared to baseline levels 
                 # P < 0.05, laparoscopy versus conventional 
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Figure 2: IL-8 levels in mean ± SEM 
 
                # P < 0.05, laparoscopy versus conventional 
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Interleukin-6 
 
Preoperative      Day +1                   Day +4 
Laparoscopy 
 
Serum  
 
PDF  
 
 
 
2.4 ± 0.3 
 
 
     83   ± 7¶  
 
82.400 ± 28.553 
 
  
 
         6 ± 1¶ 
 
65.600 ± 17.583 
Conventional 
 
Serum  
 
PDF 
 
 
 
6.4 ± 2.6 
  
 
      105  ± 33¶ 
 
139.909 ± 34.026 
 
  
 
       17 ± 6¶ 
 
80.272 ± 28.277 
  
Table 2: Peritoneal Drain Fluid (PDF) 
                IL-6 levels in pg/ml 
                ¶ P < 0.05, serum versus PDF               
 
 
 
 
Interleukin-8 
 
Preoperative   Day +1     Day +4 
Laparoscopy 
 
Serum 
 
PDF 
 
 
135 ± 56 
 
  
     67  ± 27¶  
 
 4.209 ± 1.127 
 
 
     134 ± 59¶ 
 
17.972 ± 2.385# 
 
Conventional 
 
Serum  
 
PDF 
 
 
 
126 ± 41 
 
 
    121 ± 40¶ 
 
 7.312 ± 1.511 
  
 
  
      90 ± 30¶ 
 
  8.547 ± 2.457 
   
Table 3: Peritoneal Drain Fluid (PDF) 
                IL-8 levels in pg/ml 
                ¶ P < 0.05, serum versus PDF   
                # P < 0.05, laparoscopy versus conventional 
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The CRP plasma levels are depicted in Figure 3. Both the laparoscopic and conventional 
procedure resulted in increased plasma CRP levels, both with a significant peak increase on 
day +1 (LP, P=0.003, CO, P=0.001) and on day +4 (LP, P=0.003, CO P=0.001) when 
compared to baseline values. No differences between the two procedures were observed. 
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Figure 3: CRP levels in mean ± SEM 
                 * P < 0.05, postoperative values compared to baseline levels 
 
 
Phenotyping of Immune Cells 
To assess the cellular inflammatory response of all the twenty-six patients, WBC, lymphocyte 
subpopulations, NK-Cells and CD14 counts were measured and depicted in Table 4. WBC 
counts increased on day +1, (LP, P=0.04, CO, P=0.001) in both groups. On day +4, WBC 
counts normalized after laparoscopy, whereas counts remained elevated in the conventional 
group (P=0.02).  
Total lymphocyte counts dropped on day +1 in both groups, as compared to preoperative 
values (LP, P=0.007, CO, P=0.006). Again, normalization had begun on day +4 in the 
laparoscopic group, whereas total lymphocyte numbers remained low in the conventional 
group (P=0.003) when compared to preoperative levels. The ratio of the lymphocyte 
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subpopulations expressing CD4 and CD8 was not significantly changed in either the 
laparoscopic or the conventional group, depicted in Figure 4. 
After 2 hours, an initial selective increase of NK-cell (CD3neg, CD16/56pos) counts in both 
groups was observed. On day +1, a transient decrease in NK counts the laparoscopic group  
(P=0.01) was observed when compared to preoperative values. In the conventional group, 
NK-cell counts still showed a decrease on day +4 (P=0.02), whereas NK cells had already 
normalized by this time in the laparoscopic group. 
Increased CD14 counts were already observed 2 hours after laparoscopy and peaked on  
day +1 (P=0.01); however, in the conventional group, no significant CD14 changes were 
observed. CD19 counts decreased (P=0.02) in the control group only, observed 2 hours after 
the procedure. 
None of the immune cell parameters showed significant differences between the laparoscopic 
and conventional procedures. 
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Figure 4: CD4/CD8 ratio in percentage of preoperative value 
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 Treatment 
Group 
Preoperative 2 Hrs p.o. Day +1 Day+4  
WBC LP 
 
CO 
 
5.7 ± 0.7 
 
6.4 ± 0.6 
7.1 ± 0.8 
 
8.0 ± 0.8 
8.4 ± 0.6* 
 
9.9 ± 0.8* 
6.8 ± 0.7 
 
8.3 ± 0.8* 
Lymphocytes 
(total) 
LP 
 
CO 
 
1.5 ± 0.2 
 
1.4 ± 0.1 
1.0 ± 0.1 
 
1.3 ± 0.2 
0.8 ± 0.1* 
 
0.9 ± 0.1* 
1.1 ± 0.2 
 
0.9 ± 0.1* 
CD4 LP 
 
CO 
 
761 ± 120 
 
654 ± 79 
388 ± 38* 
 
458 ± 74* 
351 ± 38* 
 
305 ± 27* 
485 ± 98* 
 
404 ± 47* 
CD8 LP 
 
CO 
 
349 ± 44 
 
429 ± 54 
333 ± 54 
 
402 ± 74 
197 ± 21* 
 
253 ± 31* 
258 ± 36 
 
288 ± 43* 
NK-Cells 
(CD3neg,CD16/56pos) 
LP 
 
CO 
 
212 ± 34 
 
211 ± 41 
263 ± 70 
 
272 ± 89 
106 ± 13* 
 
155 ± 23 
240 ± 89 
 
154 ± 24* 
CD19 LP 
 
CO 
 
222 ± 44 
 
140 ± 21 
128 ± 18 
 
104 ± 19* 
191 ± 39 
 
128 ± 25 
217 ± 54 
 
122 ± 17 
CD14 LP 
 
CO 
312 ± 44 
 
442 ± 53 
375 ± 88 
 
377 ± 42 
589 ± 56* 
 
535 ± 67 
413 ± 58 
 
532 ± 55 
Table 4: Results are expressed as mean ± SEM   
               LP = Laparoscopy, CO = Conventional, p.o. = postoperative                           
               White Blood Cell Count (WBC) and lymphocytes in 106/ml  
               CD4+, CD8+, CD14+, CD19+ and NK-cells in 103/ml   
               * P < 0.05, postoperative values compared with preoperative levels 
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HLA-DR Expression 
Monocyte HLA-DR expression was used as a parameter for trauma-induced immune 
suppression and is depicted in Figure 5. The figure shows postoperative HLA-DR expression 
on monocytes expressed as a percentage of preoperative values set at 100 percent. In both 
groups, HLA-DR expression decreased within two hours (LP, P=0.01, CO, P=0.02). After 
laparoscopy, HLA-DR expression was still decreased on day +1, (P=0.05). On day +4 no 
significant decrease was found, suggesting normalization of the HLA-DR expression. Upon 
conventional surgery, the HLA-DR expression remained suppressed at least until day +4  
(day +1, P=0.002 and day +4, P=0.01). 
Significant differences were not observed between the groups. 
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Figure 5: HLA-DR expressions in percentage of preoperative value 
                * P < 0.05, postoperative values compared to baseline levels 
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DISCUSSION 
In this study, the patients who underwent laparoscopic colon carcinoma resection enjoyed a 
shorter hospitalization time than patients who underwent conventional surgery. This 
observation is in accordance with other laparoscopic vs open colorectal resection studies.15-17 
Even if the clinical advantages of laparoscopic approach are clear in procedures such as 
cholecystectomy or Nissen fundoplication, in which a grade of immunologic preservation is 
recorded, in more advanced laparoscopic procedures such as colon resection, these advantages 
become less apparent and sometimes conflictive. 
Extensive randomized studies are ongoing in order to demonstrate whether laparoscopic colon 
resection for cancer is better or worse than or equal in advantages to the conventional 
approach and to give answers concerning cancer survival. Along with this question, the study 
of the biologic consequences will offer more insight in the possible advantages of these two 
different procedures. 
The production of the pro-inflammatory cytokines IL-6, TNF-α, and CRP are accurate 
markers of the overall acute-phase response and cytokine levels in the circulation are used to 
monitor the impact of surgical trauma.18 In this study, the serum IL-6 levels taken two hours 
after surgery were significantly lower after laparoscopic surgery than after conventional 
surgery and therefore considered less traumatic.  
Localized productions of pro-inflammatory cytokines in the PDF after surgical trauma have 
not been well characterized. The inflammatory cascade is initiated by IL-1 and TNF-α, 
followed by IL-619 and IL-8. Peritoneal mesothelial cells, fibroblasts, macrophages and 
leucocytes are the probable sources of local cytokine.20,21 Several studies have reported 
significant postoperative TNF-α levels measured in wound and peritoneal fluids; however, 
perioperative circulatory TNF-α changes were undetectable.12,22,23 In this study, serum and 
PDF TNF-α levels were undetectable in both groups. This can be explained by the production 
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of soluble TNF receptors I & II that are shed in the circulation in response to the same stimuli 
that are known to induce TNF-α. This may compete with other cellular receptors for the 
binding of free TNF-α.24 
Serum IL-6 is significantly lower two hours after laparoscopic surgery, suggesting that the 
laparoscopic approach is initially less traumatic than conventional surgery. In the following 
days a diminished IL-6 difference between the two groups is in concordance to a previous 
study of ours.25 
In both groups, the IL-6 levels in PDF were about a thousand-fold higher than the serum 
levels. This supports the idea that IL-6 is generated locally and is compartmentalized in 
response to trauma. Interestingly, no differences were found in PDF on day +1 and +4 
between the two groups. This suggests that the local dissected area  may be equal after 
laparocopic and conventional colon surgery. The difference between IL-6 levels in the PDF 
and serum observed at day +4 is remarkable. IL-6 levels in PDF were still highly elevated 
whereas the IL-6 levels in serum nearly reached preoperative values at day +4. This 
observation suggests that circulatory IL-6 is a pivotal factor for the liver to generate CRP; the 
increased local IL-6 may play a role in local immune cell recruitment and wound healing.  
IL-8 is a potent chemoattractant for neutrophil and lymphocyte as well as an angiogenic 
growth factor promoting wound healing.26,27 A couple of observations regarding IL-8 levels 
can be made from this study. Firstly, local IL-8 expression is much higher than levels 
measured systemically. Finding higher IL-6 and IL-8 expression in the PDF supports the 
above-mentioned idea of compartmentalization of cytokines within the abdominal cavity. This 
suggests that IL-6 and IL-8 measured systemically represent only a small fragment of what is 
generated locally. The precise mechanism of compartmentalization is unclear. It is 
conceivable that high local cytokines production and/or the disrupted lymph drainage system 
and vascular continuity, due to surgical trauma, may prevent transfer into the circulation. The 
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localized production stimulates the influx of immune cells,28,29 which in turn express 
cytokines and growth factors beneficial for wound healing and host defense. Secondly, IL-8 
PDF levels increase in the postoperative period. The prolonged and increased IL-8 expression 
in the PDF suggests additional cell sources such as endothelial cells and fibroblasts30 
contributing to the wound healing process. Finally, the significantly lower systemic IL-8 
level, two hours postoperatively and higher IL-8 expression in the PDF at day +4 after 
laparoscopic surgery compared to the conventional approach is unclear. It is tempting to 
speculate on correlations with pneumoperitoneum, or longer surgical injury and exposure to 
anesthesia.  
It is unclear to what extent the peritoneal fluid drain contributes to the cytokine production; 
however, it is unlikely that the drain itself causes the thousand folds increase. 
CRP is a regulatory component of the innate immune system and participates in tissue repair 
and regeneration as well.31 In this study, CRP levels were significantly elevated in the 
postoperative days following laparoscopic and open colon resection; however, no differences 
between the groups were found. This was in contrast to our previous study that showed 
significantly lower CRP levels after laparoscopic Nissen fundoplication compared to the 
conventional procedure observed at day +1.6 An explanation for this difference is probably 
due to trauma size, since Nissen fundoplication is considered less traumatic than colectomy. 
Both surgical procedures affect the systemic cellular immune numbers and usually a 
postoperative rise in WBC and a decrease in total lymphocytes are found.3,10 In this study, 
normalization in WBC and total lymphocyte levels was achieved earlier after laparoscopy 
than conventional surgery.  
Remarkably, the postoperative CD4/CD8 ratio did not change significantly in either group. 
Often the proportion of CD4 lymphocyte decrease is greater than that of CD8 lymphocytes 
and it is suggested that the magnitude of the CD4/CD8 ratio drop is related to the size of the 
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surgical trauma.3 The observation of increased CD8 and reduced CD4 activity was more 
pronounced after conventional cholecystectomy when compared to the laparoscopic 
approach.32 
HLA-DR expression on monocytes was measured to assess whether the reduced inflammatory 
response would be associated with a preservation of postoperative presenting antigen capacity 
of the monocytes. It has been demonstrated that reduced HLA-DR expression and slow 
restoration to baseline values after surgery are associated with an increased incidence of 
infection.33,34 We have shown previously that HLA-DR expression was better preserved after 
laparoscopic cholecystectomy than the conventional approach.35 And in a previous 
laparoscopic versus conventional study of Nissen fundoplication, we observed that after 
postoperative HLA-DR decrease in both groups, HLA-DR restoration occurred earlier (within 
one day) in the laparoscopic group.  
In the present study on colectomy, HLA-DR restoration was observed in the laparoscopic 
group on day +4. The degree of operative trauma may determine the rate of HLA-DR 
restoration, since colectomy is considered major trauma and Nissen fundoplication moderate. 
Between the groups we did not find statistical differences in HLA-DR expression at the fourth 
postoperative day, as in the Ordeman study.10 
In conclusion, in clinical terms, the patients who underwent laparoscopic surgery enjoyed a 
shorter hospitalization. Immunologically, large amounts of pro-inflammatory cytokines are 
produced in the peritoneal drain fluid after both procedures and the systemic responses after 
both surgical approaches are a small reflection of these local events. In the early postoperative 
period the pro-inflammatory cytokines levels generated locally suggests that both approaches 
is equally traumatic. No differences in cellular response between the two groups were 
observed. 
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ABSTRACT 
 
Background: Vascular endothelial growth factor (VEGF) and endostatin are 
respectively known as an important endogenous stimulator or inhibitor of angiogenesis. 
Angiogenesis is essential for wound healing. 
The aim of this study was to study the effect of the extent of operative trauma (laparoscopic 
versus conventional Nissen fundoplication) on the angiogenic balance of VEGF and 
endostatin in plasma.  
Methods: Sixteen patients with gastro-esophageal reflux disease were randomly 
assigned to undergo either a laparoscopic or a conventional procedure. Postoperative 
inflammatory response was assessed by measuring white blood cells (WBC) and C-reactive 
protein (CRP). Plasma VEGF and endostatin levels were monitored by an enzyme-linked 
immunosorbent assay.  
Results: CRP levels one day after surgery were significant lower after laparoscopy 
compared to conventional surgery (P=0.01). WBC and endostatin were not different in both 
groups. The VEGF level was decreased two hours after the operation in the laparoscopic 
group (P=0.04) and returned to preoperative values 24 hours later (P=0.03). In the 
conventional group, VEGF levels increased four days after surgery (P=0.01).  
Conclusion: The extent of the operative trauma influences the VEGF response to 
surgery. No significant change in endostatin levels was seen. 
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INTRODUCTION 
The formation of new vessel from pre-existing capillary vessels is called angiogenesis. 
Angiogenesis plays an important role in a variety of processes such as wound healing and 
tumor growth.1 Under physiological conditions, adult endothelial cells (ECs) are quiescent 
and do not proliferate. In response to various stimuli such as trauma and hypoxia, quiescent 
ECs become activated.  
Vascular endothelial growth factor (VEGF) is considered the most potent inducer of 
angiogenesis, since it stimulates EC proliferation, migration and tube formation.2 
Furthermore, the importance of VEGF enhances vascular permeability which induces local 
effusion of various plasma proteins and consequently migration of endothelial cells into the 
injured area.3 Studies have indicated that VEGF is involved early in the wound healing 
process. 
In response to trauma, platelets aggregate and release growth factors, such as platelet derived 
growth factor (PDGF), platelet derived-endothelial cell growth factor (PD-ECGF) and VEGF 
which are contained within the α-granules of platelets.4,5  
Subsequently, peripheral white blood cells (WBC), such as granulocytes, B and T-
lymphocytes and monocytes will shortly appear in the injured area. Each type of cells are also 
able to release VEGF from their secretory granular compartment.6,7,8 In addition, pro-
inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor 
necrosis factor-α (TNF-α) are released locally following trauma. All these cytokines are able 
to induce VEGF expression.9-11    
Devitalized peripheral tissue is exposed to hypoxia. Tissue pO2 is usually low in the centre of 
the wound, increasing gradually as the wound heals. Under hypoxic in vitro conditions, not 
only host-derived cells but also tumor cells express VEGF.12,13,14 
In contrast to VEGF, endostatin is a potent endogenous anti-angiogenic cytokine. 
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Endostatin specifically inhibits EC proliferation, migration and tube formation in vitro. 
Furthermore it has the ability to suppress tumor growth.15 
All together, we suppose that the cellular import and cytokines generated locally will result in 
a net balance of pro-angiogenic over anti-angiogenic stimuli, which promotes wound healing.   
It is well accepted that laparoscopic surgery reduces the extent of the surgical trauma in 
comparison to the conventional technique. It can therefore be speculated that a minor trauma 
will result in a slighter release of angiogenic factors.  
The aim of this randomized study was to compare the influence of laparoscopic and 
conventional Nissen fundoplication on the production of VEGF, endostatin, and the 
generation of CRP and white blood cells (WBC), representing the  inflammatory response. 
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PATIENTS AND METHODS 
Sixteen patients with gastro-esophageal reflux disease who were randomly assigned as a part 
of a large national randomized study of laparoscopic versus conventional Nissen 
fundoplication were included in this study. Demographic data and operation times are shown 
in Table 1. The operative fundoplication was performed according to the Nissen-Rossetti 
technique.16    
None of the patients received heparin or corticosteroids. None were known to suffer from 
diabetes mellitus, malignancy or cardiovascular disease. The protocol was approved by the 
institutional review committee of our hospital. Informed consent was obtained from all 
patients. 
Peripheral heparinized blood samples (Vacutainer, Becton Dickinson, Rutherford, NJ, USA) 
were collected preoperatively (baseline), and 2 hours, 1 day and 4 days after surgery. Plasma 
samples were processed immediately after collection by centrifuging at 2000 r.p.m. for 10 
minutes and then stored at -80°C until processing. Repeated freezing and thawing was 
avoided. 
 
Clinical data  Conventional        Laparoscopic 
    (n=8)                    (n=8) 
Age (years) 
Male/Female 
Surgery Time (min) 
Hospital Stay (days) 
 41 ± 13                      39 ± 9               
     5/3                           5/3 
105 ± 25                   125 ± 18 
 5.5 ± 0.8                    5.0 
Table 1: Demographic data 
    The data are presented as mean ± SEM 
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VEGF  
Plasma VEGF165 levels were measured using a commercially available enzyme-linked 
immunosorbent assay (ELISA) kit (R & D system Minneapolis, MN). Optical density was 
measured at 450 nm using a Spectra Fluor, Tecan plate reader, according to the 
manufacturer’s recommended protocol.  
 
 
Endostatin  
Endostatin was measured using a commercial available enzyme-linked immunosorbent assay 
(ELISA kit, Cytimmune, College Park, Maryland, U.S.A.). The procedure was according to 
the manufacturer’s recommended protocol.  
 
 
Pheriperal white blood cell count (WBC) 
WBC was measured using a Coulter blood analyzer (Coulter, Bastingstoke, England). 
 
 
C-reactive protein (CRP) 
CRP plasma levels were measured by the immunoturbidimetric method, using the BM/Hitachi 
705 (Boeringer, Mannheim, Germany). 
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STATISTICAL ANALYSIS 
The results are reported as mean ± SEM. The “Statistical Package for the Social Sciences” 
(SPSS 7.5 tm) was used to analyze the data. Differences within groups were analyzed by the 
Wilcoxon Signed Ranks Test for two related samples. Differences between the groups were 
analyzed by means of a two-way analysis of variance. When significant differences between 
the two groups were found, the two-sample Mann-Whitney U test was used. Significance was 
accepted at a two-tailed P<0.05. 
 
RESULTS 
None of the patients suffered any major complications or needed postoperative blood 
transfusions; one patient in the conventional group had a wound abcess that resolved after 
draining. VEGF, endostatin levels are shown in Table 2, WBC counts and CRP levels are 
shown in Figure 1 and 2, respectively. 
 
 Groups Preop.  2 Hours Day 1 Day 4 
VEGF CO 
LP 
60 ± 23 
78 ± 29 
79  ± 37 
26  ± 17* 
 53  ± 16 
 79  ± 22# 
102±21*  
 55 ± 22 
Endostatin 
 
CO 
LP 
21 ± 4.7 
17 ± 2.2 
21  ±  3.7 
18  ±  1.5 
16 ± 3.0 
16  ± 2.9  
21 ± 3.7 
20 ± 2.5  
Table 2: Results Mean ± SEM     
   CO = Conventional, LP = Laparoscopic 
   VEGF in pg/ml, Endostatin in ng/ml 
   * P < 0.05, postoperative value compared to preoperative values 
   # P < 0.05, day +1 value compared to 2 hours after the operation 
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Figure 1: Significant differences in WBC were found postoperatively. In both groups there is  
 
     an increase of WBC observed 2 hours and day +1. 
     * P < 0.05, postoperative levels compared to preoperative levels 
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Figure 2: The postoperative inflammatory response is activated on day +1. A significant  
 
     difference between laparoscopic and conventional surgery were found. After  
     laparoscopic surgery CRP levels increases however not as high as in the  
     conventional group. 
     ¶ P < 0.05, laparoscopic versus conventional surgery 
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Vascular Endothelial Growth Factor 
VEGF levels decreased significantly two hours after the laparoscopic procedure (P=0.04) and 
returned to the preoperative levels at day+1 (P=0.03).  
In the conventional group, VEGF levels increased significantly four days after surgery in 
comparison with the preoperative values (P=0.01).  
No correlation between VEGF and WBC or CRP levels was found. 
 
Endostatin 
No significant changes were found in the conventional group and in the laparoscopic group. 
 
White Blood Cell count (WBC) 
As expected, WBC significantly increased in the early postoperative period following the 
laparoscopic and conventional procedure. The same pattern of WBC increase was seen two 
hours and one day after surgery. 
 
C-Reactive Protein (CRP) 
Both surgical procedures resulted in a significant increase in CRP levels on day +1 when 
compared to the preoperative levels. However, the CRP response was significantly less 
extensive after laparoscopic surgery compared with the conventional procedure on day +1  
(P=0.01). On day +4 the CRP levels in the conventional group were still increased compared 
to the laparoscopic group.  
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DISCUSSION 
The goal of this study was to evaluate the effect of a minor and major trauma on circulatory 
VEGF and endostatin levels of patients with a benign disease. The knowledge about the effect 
of a surgical trauma and subsequent wound healing on the local and systemic angiogenic 
balance is limited. 
The healing of the wound is a complex process and has three consecutive phases, first 
hemostasis and inflammation (days 0-3 after injury), second the proliferative phase leading to 
re-epithelialization and granulation formation (days 3-14 after injury) and finally scar tissue 
remodelling (days 7-30 after injury).17,18 
The points at which VEGF and endostatin were assessed (preoperative, 2 hours postoperation, 
day +1 and day +4) allowed us insight in these circulatory angiogenic factor levels in the first 
two phases of wound healing.   
A Nissen fundoplication procedure induces an inflammatory response, which was monitored 
by means of plasma CRP and WBC. In both groups, WBC increased equally postoperatively. 
The increase in CRP was more pronounced in the patients undergoing the conventional 
procedure, as could be expected after major surgery.19,20  
With respect to VEGF, two significant observations could be made. Firstly, in the 
laparoscopic group there was a significant decrease in VEGF level two hours after operation, 
returning to preoperative values on day +1. Secondly, a significant increase in VEGF level 
was found at day +4 after conventional Nissen procedure. The first observation may be 
correlated to insufflation of CO2 for establishing a pneumoperitoneum. Taura et al. 
demonstrated that CO2  insufflation at 15 mm Hg caused increased plasma lactic acid which 
reached its highest value 60 minutes after the operation.21 Others have confirmed that 
increased intra-abdominal pressure due to CO2 insufflation resulted in higher PaCO2 in the 
postoperative period after laparoscopic approach.22,23 The decrease of VEGF two hours after 
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the laparoscopic operation may be explained through direct effects of CO2  due to insufflation. 
The increase of VEGF to preoperative level on day +1 may be due to the postoperative effect 
of acidosis on endothelial cells. D’Arcangelo et al. demonstrated in vitro that hypercarbic 
acidosis will induces VEGF expression in bovine aortic endothelial cells (BAECs).24 
The significant increase of VEGF at day +4 only found in the conventional group may be 
related to the extent of operative trauma. A recent study has shown a transient postoperative 
increase in serum VEGF levels on the first and third day after major vascular surgery in 
contrast to minor changes after less extensive surgery.25 
VEGF is also involved in malignancy.26 Different tumors are able to produce VEGF and a 
relationship has been suggested between tumor progression and VEGF levels.27 Maniwa et al. 
showed that in patients with lung cancer, the increase of VEGF levels after radical surgery 
may have a detrimental effect on outgrowth of micrometastases.28  
In contrast with the pro-angiogenic factor VEGF, endostatin is considered an important anti-
angiogenic factor. Endostatin is produced by enzymatic digestion of a protein precursor, 
collagen XVIII, and has been shown to reside from basement membranes, vessel walls and 
mostly in the liver.29,30 The mechanisms of endostatin generation in vivo are unknown. 
Finding endostatin levels in the circulation is interesting and suggests that it may serve as an 
homeostatic angiogenic control. Theoretically, a net balance of pro-angiogenic over anti-
angiogenic factors, would switch in the on position, hereby facilitating wound healing. 
Nevertheless, in this study the level of endostatin was not influenced by the two surgical 
techniques. 
In conclusion, the levels of VEGF, WBC and CRP change after surgery and the amount of 
surgical trauma influences the degree of these postoperative changes. The unexpected 
decrease of VEGF levels immediately after laparoscopic surgery along with unchanged 
endostatin levels awaits confirmation by additional studies.  
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ABSTRACT 
 
Background and Objectives: Angiogenesis is essential for wound repair after 
surgical trauma. Vascular endothelial growth factor (VEGF) and endostatin are endogenous 
angiogenic factors involved in the initiation and completion of angiogenesis. The aim of this 
study was to examine the local and systemic VEGF and endostatin profiles in patients 
undergoing surgery for benign and malignant breast processes.  
Methods:  A total of sixteen patients with or without cancer underwent breast surgery. 
Group I: eight patients with primary breast cancer underwent a simple or radical mastectomy 
according to Madden including dissection of axillary lymph nodes. Group II: eight healthy 
female-to-male transsexuals underwent subcutaneous mastectomy. VEGF and endostatin 
levels in plasma and wound fluid were determined. 
Results: In both groups VEGF levels in wound fluid were significantly higher 
compared to postoperative plasma levels, whereas wound fluid endostatin levels were lower 
than plasma levels and decreased progressively after surgery.  In both groups plasma VEGF 
and endostatin levels did not change significantly. 
  Conclusions: The local VEGF increase and endostatin decrease observed immediately 
after surgery appears to be a physiological response to operative trauma, which can be studied 
more profoundly in locally generated fluid than in blood. This process did not seem to be 
influenced by the type of process (cancerous or non-cancerous) involved in the surgical 
intervention.  
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INTRODUCTION 
 
Angiogenesis in wound repair is essential to restore the delivery of oxygen and nutrients and 
the removal of waste products from the injured area. Numerous cells and cytokines are 
involved during the three phases of wound healing and the balance of stimulatory or 
inhibitory cytokines will determine each phase of the wound healing process.1,2 VEGF is a 
cytokine that is considered the most potent inducer of angiogenesis, since it specifically 
stimulates endothelial cell (EC) proliferation, migration and tube formation.3 Furthermore, 
VEGF enhances vascular permeability, which induces local effusion of various plasma 
proteins, facilitates the migration of endothelial cells into the injured area4 and stimulate 
granular tissue formation.5 Moreover, in oncology, tumors produce constitutively VEGF as a 
consequence of their aberrant genetic profile and because of hypoxia inside tumor tissue. The 
VEGF level is found to correlate with tumor progression.6,7 
Endostatin, the C-terminal fragment of collagen XVIII, is a potent angiogenesis inhibitor. 
Hepatocytes are a major source of collagen XVIII and may contribute to endostatin levels in 
the circulation.8 Endostatin specifically inhibits EC migration in vitro9 and potently inhibits 
tumor growth in various animal models.10  
In the present study we examined the VEGF and endostatin profile in wound fluid and plasma 
of patients undergoing curative breast cancer surgery and female-to-male mastectomy. The 
main interest was to compare the angiogenic profile in wound fluid with the pattern in the 
circulation. 
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PATIENTS AND METHODS 
The ethical committee of the Vrije Universiteit Medisch Centrum (VUMC) approved the 
protocol. Informed consent was obtained from all patients.  
Group I consisted of eight patients with primary breast ductal carcinomas. A simple 
mastectomy was carried out on four patients and a drain was left in the resected area. Four 
other patients underwent a radical mastectomy according to Madden.  
Group II consisted of eight healthy female-to-male transsexuals who underwent a mastectomy 
by a transareolar approach to achieve a male chest figure.  
The mastectomies in this group were performed on both breasts and a drain was placed at 
each side. The wound fluid was collected from the side with the highest wound fluid 
production. Group II received an androgen supplement (Sustanon 250 mg i.m., Organon, 
The Netherlands)  twice a month as part of the sex reassignment treatment.  
EDTA blood samples were collected preoperatively (baseline), and 1 day and 4 days after 
surgery. Twenty-four hours of wound fluid production was collected on postoperative days 1 
and 4. Plasma and wound fluid samples were centrifuged at 2000 rpm for 10 minutes and then 
stored at -80°C. Freezing and thawing was avoided. 
 
Detection of VEGF and endostatin  
VEGF165 and endostatin levels in plasma and wound fluid were measured using a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit (R & D system 
Minneapolis, USA). Both intra- and inter-assay variance was less than 10%. The minimum 
detectable VEGF level is 9.0 pg/ml and endostatin level is 1.95 ng/ml. The local VEGF and 
endostatin concentration may be affected by a dilution effect of wound fluid production in 
both groups. Therefore the total VEGF and endostatin production was calculated by 
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multiplying the concentration by volume for each individual patient, followed by calculating 
the mean of the levels. 
 
STATISTICAL ANALYSIS 
The results are reported as mean ± standard error of the mean (SEM). Overall differences 
between groups were analyzed by means of a two-way analysis of variance, and if a 
significant overall difference between groups was found, the two-sample Mann-Whitney U 
test was used. The Wilcoxon Signed Ranks Test for two related samples analyzed differences 
within groups. Significance was accepted at a two-tailed P < 0.05.  
 
RESULTS 
The mean age of the patients included was 51.6 ± 4.9 years for group I and 36.6 ± 4.9 for 
group II, P=0.04. The average operating time was 128.8 ± 10.9 minutes for group I and 199.3 
± 17.5 minutes for group II, P=0.01. None of the patients experienced any postoperative 
complication.  
The wound fluid production within group I, obtained from the simple mastectomies, (day 1: 
70.0 ± 35.6 ml and day 4: 38.8 ± 20.2 ml) and radical Madden mastectomies, (day 1: 90.0 ± 
25.8 ml and day 4: 63.8 ± 53.1 ml) was not significantly different. 
Four days after surgery the wound fluid production was higher in group I, P=0.001 when 
compared to group II, displayed in Figure 1. 
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Figure 1:  # P < 0.05, differences between the groups 
      * P < 0.05, day +4 compared to day +1                
 
In both groups, the mean VEGF level in wound fluid was much higher compared to plasma 
(Table 1). In group I, an eight-fold VEGF increase in wound fluid, P=0.004, compared with 
plasma level was found one day after surgery. After four days, this difference increased to 
twenty-four-fold, P=0.018.   
In group II, the wound fluid VEGF level increased by eighteen-fold one day after surgery,  
P=0.001 and thirty-two-fold four days after surgery, P = 0.001, compared to the plasma level 
of the corresponding day. In both groups, the VEGF concentration in wound fluid was higher 
at day four compared to day one after surgery, P=0.031. The VEGF levels in plasma and 
wound fluid were not significantly different between both groups. 
In group I, endostatin wound fluid levels were lower than plasma one day, P=0.03, and four 
days, P=0.004 after surgery. The wound fluid endostatin level decreased after four days 
compared to day one after surgery, P=0.03.  In group II, the endostatin wound fluid level was 
lower than the plasma level, four days after surgery, P=0.004. In both groups the wound 
endostatin levels decreased significantly from day one to four days after surgery. 
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Prior Surgery Day +1    Day +4        
VEGF 
Group I:  
Plasma 
 
Wound fluid             
 
Wound fluid (total in pg) 
 
 
 
195.7 ± 42.8 
 
 
 
     
    121.5 ±     39.6 ¶ 
 
    963.9 ±   187.4  
 
   80834 ± 17343 
     
 
 
      132.2 ±     58.1 ¶ 
 
    3108.2 ±   703.3 * 
 
   123164 ± 44326 
VEGF 
Group II: 
Plasma 
 
Wound fluid 
 
Wound fluid (total in pg) 
 
 
 
136.9 ± 50.4 
 
  
      62.2 ±    13.6 ¶ 
 
  1121.3 ±  120.9 
 
   55297 ±  3003 
    
 
   
        95.7 ±     39.7 ¶ 
 
    3098.9 ±   488.1 * 
 
     38289 ±   7202 
Endostatin 
Group I: 
Plasma 
 
Wound fluid  
 
Wound fluid 
(total in ng)            
 
 
 
31.4 ± 2.7 
 
 
      23.1 ±  2.5 ¶ 
 
      17.3 ±  1.3  
 
     1363 ±  215 
 
 
        28.5 ± 3.1 ¶  
 
        11.8 ± 1.2 * 
 
         437 ± 92 * 
Endostatin 
Group II: 
Plasma 
 
Wound fluid 
 
Wound fluid 
(total in ng) 
 
 
 
23.9 ± 2.3 
 
 
      16.9 ±   1.7 
 
      16.8 ±   1.7 
 
       879 ± 146 
 
 
        31.7 ± 5.6 ¶ 
 
        12.7 ± 1.7* 
 
         162 ±  39 * 
 Table 1: Mean ± SEM 
                VEGF in pg/ml, Endostatin in ng/ml 
                ¶ P < 0.05, differences between wound fluid and plasma levels  
                * P < 0.05, day +4 compared to day +1 
                Total  = concentration x wound fluid production    
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DISCUSSION 
Angiogenesis plays an important role in the process of wound healing. Insight into the 
mechanisms of angiogenesis is increasing, but little is known about how local angiogenesis 
initiated in the wound influences the systemic angiogenic parameters after operative trauma. 
We evaluated the profiles of VEGF and endostatin in wound fluid and plasma from patients 
operated for breast cancer or transsexual patients undergoing a double mastectomy. 
Wound fluid production in the group with cancer was significantly higher four days after 
surgery. The fact that their wounded area is larger may explain this. 
In this study, the plasma VEGF level was not significantly different between the two groups. 
It is unknown whether testosterone treatment in women (group II) has an effect on VEGF 
production.  
The systemic VEGF levels after breast surgery did not change significantly, however, the 
large difference between VEGF in plasma and in wound fluid observed postoperatively in 
both groups, is remarkable. It appears that the concurrently measured plasma VEGF reflects 
only a fragment of what is generated locally. Local VEGF generation after a surgical 
procedure is probably due to instant platelet degranulation, production by recruited immune 
cells and indirectly by the expression of pro-inflammatory cytokines and local hypoxia due to 
devitalized tissue.11-13 In this study it was unlikely that residual tumor was another source of 
VEGF, since the surgical margins were free of tumor. 
The role of a high VEGF level in the wound may have two functions, one to initiate 
angiogenesis and another to temper the local immune response in the injured area. The 
devitalized tissue and exposed self-antigens in a wound contain an intense immunologic 
stimulus. VEGF may act as an immunosuppressive agent14,15 that prevents a local autoimmune 
reaction.  
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In advanced cancer patients, the VEGF level increase may have negative consequences. A 
recent in vitro study showed that breast cancer cells stimulated by VEGF had an increased 
invasive character.16 In addition, a VEGF increase induced by surgery resulted in a rapid 
outgrowth of micrometastases, which could be abolished by an angiogenesis inhibitor.17  
Endostatin levels were also investigated in plasma and wound fluid. Preoperative plasma 
endostatin levels were not significantly different between the groups and did not change 
significantly after surgery. However, in contrast to VEGF, endostatin levels decreased in 
wound fluid in both groups. The mechanism of the decrease of local endostatin levels is 
unclear. It may be the effect of the expression of various proteolytic enzymes1,18 during 
wound healing that degrade endostatin. Anyhow, the decrease of endostatin in the early phase 
of wound healing seems to be a physiological response to injury. Together, the strong increase 
in local VEGF and decrease in endostatin supports the idea of a physiological tissue 
angiogenic switch in the first phase of wound healing. These changes were comparable in 
both groups, which confirm the idea that wound healing after radical surgery for normal and 
malignant indications develops through similar physiological mechanisms. 
In conclusion, the pattern of change in VEGF and endostatin levels in wound fluid was 
similar in both patient groups. Wound fluid was much more informative than blood, which 
emphasizes wound fluid as a “conditioned medium” of this physiological process. In addition, 
this study showed that angiogenesis is started immediately after surgery. This process did not 
seem to be influenced by the type of process, cancerous or non-cancerous) involved in the 
surgical intervention. 
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ABSTRACT 
Background and Objectives: Angiogenesis is essential for wound healing. Vascular 
endothelial growth factor and endostatin are both endogenous angiogenic factors, thought to 
be involved in the initiation, respectively termination of angiogenesis. The aim of this study 
was to assess the local and systemic angiogenic profile in patients undergoing laparoscopic or 
open surgery for colon cancer. 
Methods:  Patients with a primary colon carcinoma were prospectively randomized to 
curative laparoscopic (n = 12) or conventional (n = 14) resection. Vascular endothelial growth 
factor and endostatin levels in serum and wound fluid were investigated. 
Results: In both groups vascular endothelial growth factor levels in wound fluid were 
significantly higher compared to postoperative serum levels, whereas endostatin levels in 
wound fluid were lower than serum levels and decreased progressively after surgery. The 
vascular endothelial growth factor levels in wound fluid measured at day 4 were significantly 
higher in the laparoscopy group compared with the laparotomy patients. 
Conclusions: Wound healing is associated with a strong local increase in pro-
angiogenic factors and a decrease of anti-angiogenic factors. The investigation of locally 
produced factors offered greater insight in the process of angiogenesis during wound healing 
than could be acquired from the circulation.  
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INTRODUCTION 
Angiogenesis, the formation of new vessels from pre-existing post-capillary vessels, plays an 
important role in physiological processes such as healing of wounds and in pathological 
processes, such as tumor growth and metastases.  
Angiogenesis in wound healing is necessary to restore the delivery of oxygen and nutrients 
and the removal of waste products from the injured area. The healing of the wound is a multi-
factorial and complex process involving a cascade of events that overlap in time.1,2 Numerous 
cytokines are involved in each phase of wound repair. Among the cytokines involved in 
wound healing, Vascular endothelial growth factor (VEGF) is considered the most potent 
inducer of angiogenesis, since it specifically stimulates endothelial cell (EC) proliferation, 
migration and tube formation.3 Furthermore, VEGF enhances vascular permeability, which 
induces local effusion of plasma proteins, facilitating the migration of endothelial cells into 
the injured area.4 Multiple cells found in wounds express VEGF,3 whereas endothelial cells 
are unique in the expression of VEGF receptors, which suggests that VEGF is necessary for 
wound healing and granulation tissue formation.5 In addition, tumor cells produce VEGF and 
the tissue VEGF level is correlated with increased vessel density and tumor progression.6 
Endostatin, the C-terminal fragment of collagen XVIII, is a potent angiogenesis inhibitor. 
Hepatocytes are a major source of collagen XVIII and may contribute to endostatin levels in 
the circulation.7 In addition, endostatin levels are elevated in some cancer patients, suggesting 
that cancer cells are able to generate endostatin.8 Endostatin specifically inhibits EC migration 
in vitro9 and potently inhibits tumor growth in various animal models.10  
In summary, in the first phase of wound healing a number of activated cells produce proteins 
locally resulting in a transient, positive balance of angiogenic stimulators over angiogenic 
inhibitors, which promotes wound healing.   
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Laparoscopic surgery reduces the extent of the surgical trauma in comparison to the 
conventional technique. It may therefore be expected that minimal invasive surgery will result 
in less release of angiogenic factors. In the present study we examined the VEGF and 
endostatin profile in wound fluid and serum of patients undergoing laparoscopic and 
conventional colon cancer resection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
STUDY DESIGN 
Twenty-six patients were enrolled as part of the international multi-center COLOR (colon 
cancer laparoscopic or open resection) trial. In this prospective randomized study, patients 
were randomly allocated a computer-generated number, which assigned them to undergo 
either a laparoscopic, or conventional curative colon carcinoma resection. The Ethics 
Committee of the VU Medical Center, Amsterdam approved this protocol. Informed consent 
was obtained from all patients. Serum plain tube samples (7 ml Vacutainer Systems) were 
collected preoperatively (baseline), 2 hours, 1 day and 4 days after surgery. A low vacuum 
abdovac drainage system (Astra, Rijswijk, the Netherlands) was left at the resection site for 
peritoneal fluid drainage. Twenty-four-hour peritoneal fluid production was collected on day 
1 and 4. Serum and wound fluid samples were obtained by centrifugation for 10 minutes at 
3,000 rpm and 40C. All samples were stored in aliquots at –800C until tested. 
 
Measurement of VEGF and endostatin 
VEGF165 and endostatin levels in serum and wound fluid were measured using a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D system 
Minneapolis, USA), according to the manufacturer’s protocol. Both intra- and inter-assay 
variance was less than 10%.  
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STATISTICAL ANALYSIS 
The results are reported as mean ± standard error of the mean (SEM). The “Statistical 
Package for the Social Sciences” (SPSS 7.5 tm) was used to analyze the data. Overall 
differences between groups were analyzed by means of a two-way analysis of variance, and 
significance tested by the two-sample Mann-Whitney U test. The Wilcoxon Signed Ranks 
Test for two related samples analyzed differences within groups. Significance was accepted at 
a two-tailed P < 0.05. 
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RESULTS 
The average hospital stay for the laparoscopic group was significantly shorter than in the 
conventional group. On the first postoperative day after conventional sigmoidectomy, one 
patient required relaparotomy because of bleeding. One patient who underwent a laparoscopic 
right hemicolectomy had a wound abcess that resolved after draining. 
 
The demographic data 
 Laparoscopy Conventional 
No. Patients 
 
  12   14 
Sex (M/F) 
 
    2/10   8/6 
Age (yr) 
 
  66 ± 3  69 ± 2 
Astler-Coller 
(A:B:C) 
Males 
Females 
 
Hemicolectomy 
right 
Sigmoid resection 
 
 
  0:2:0 
  0:0:10 
 
 
  6 
  6 
 
 
  0:7:1 
  0:3:3 
 
 
  8 
  6 
 
Operative time 
(minutes) 
 
176 ± 15 143 ± 9 
Hospital stay 
(days) 
 
   9 ± 0.5#   12 ± 1 
Mean ± SEM 
# P < 0.05, laparoscopy versus conventional 
 
Peritoneal drain fluid (PDF) 
Production of PDF showed no differences between the groups at day 1 (laparoscopic 136 ± 68 
ml and open 153 ± 37 ml) and day 4 (laparoscopic 20 ± 5.7 ml and open 32 ± 7.7 ml) after 
operation respectively. 
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Angiogenic factors 
VEGF and endostatin serum levels were measured in 12 laparoscopic and 14 conventionally 
treated patients. In addition, local production of both factors was evaluated in wound fluid 
from 5 laparoscopic and 11 conventional-treatment patients.  
In both groups, VEGF levels in serum increased about 2-fold at day 4 compared with baseline 
values (P =0.001), but with no significant difference between these two groups (Figure 1). In 
the laparoscopic group, VEGF concentration in PDF was three-fold higher at day 1 compared 
with serum level at the same day. At day 4 this difference increased to seven-fold (Figure 2). 
The VEGF increase in PDF was significant at day 4 compared with day 1 (P=0.02). In the 
conventional group, wound fluid VEGF level was about three-fold higher than serum at day 1 
and at day 4 after surgery (P=0.01). The VEGF levels in PDF of the laparoscopic group at day 
4 were significantly higher than in PDF from the conventional group (P=0.02).  
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Figure 1: VEGF level in serum 
                 * P < 0.05, day +4 compared to preoperative value 
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Figure 2: VEGF level in wound fluid 
                 # P < 0.05, differences between the groups 
 
Circulating and PDF endostatin levels are depicted in Figures 3 and 4 respectively. In both 
groups serum endostatin levels were significant lower at day 1 (both, P=0.01) when compared 
with baseline values. The PDF endostatin levels decreased postoperatively in both groups to 
concentrations below the detectable level. 
 
 
 
 
 
 
 
 
 
 
 110
 
 
 
Figure 3: Endostatin level in serum 
                 * P < 0.05, day +4 compared to preoperative value 
 
 
 
 Figure 4: Endostatin level in wound fluid. N.D.= not detectable              
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DISCUSSION 
Clinical and immunologic advantages of laparoscopic approach are clear in procedures such 
as cholecystectomy or Nissen fundoplication.11,12 In more extented laparoscopic procedures 
such as colon resection for cancer these advantages are less apparent.13 Long term results of a 
randomized study of Lacy et al. has shown a significant longer survival of stage III colon 
cancer of patients who underwent laparoscopic surgery when compared to the conventional 
approach.14  
We investigated the peritoneal and systemic immune response following laparoscopic and 
conventional surgical approaches in patients with colorectal carcinoma. We found that large 
amounts of pro-inflammatory cytokines were produced in the wound fluid after both 
procedures while the systemic responses after both surgical approaches were only a marginal 
reflection of these local events. These findings suggest that the surgical wound creates a 
separate compartment from the systemic circulation in terms of inflammatory response.13  
We studied two important regulators of angiogenesis at a systemic and a local level after 
surgery. The data showed increased systemic VEGF levels postoperatively after both 
conventional and laparoscopic surgery, and significant differences were not seen between 
both approaches. VEGF levels measured in peritoneal drain fluid were much higher when 
compared to the systemic values. Local VEGF generation after a surgical procedure is 
probably due to instant platelet degranulation, production by recruited immune cells and 
indirectly by the expression of pro-inflammatory cytokines and local hypoxia found in 
devitalized tissue.15-17 It was unlikely that residual tumor was another source of VEGF, since 
the surgical margins were free of tumor. The role of a high VEGF level in the wound may 
have two functions, one to initiate angiogenesis and another to temper the local immune 
response in the injured area. The devitalized tissue and exposed self-antigens in a wound 
contain an intense immunologic stimulus. VEGF may act as an immunosuppressive agent,18,19 
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that prevents a local autoimmune reaction. The significantly higher increase of local VEGF at 
day 4 in the laparoscopy group versus the laparotomy group is interesting. This may be 
explained by the postoperative effect of local acidosis, due to CO2 insufflation, on endothelial 
cells. D’Arcangelo et al. demonstrated in vitro that hypercarbic acidosis will induces VEGF 
expression in bovine aortic endothelial cells (BAECs).20,21 
In contrast to VEGF, the systemic and, more profoundly, the local endostatin levels decreased 
during the postoperative period. The mechanism of the decrease of local endostatin levels is 
speculative. It may be due to the release of various proteolytic enzymes during wound healing 
that degrade endostatin.1,22  The local decrease of endostatin in the early phase of wound 
healing may be seen as a physiological response to injury. 
In conclusion, the strong increase of local VEGF, and the disappearance of endostatin 
highlights the concept of a physiological angiogenic switch in the first phase of wound 
healing. As was shown for immunological parameters,13 angiogenic factors detected in wound 
fluid were found at remarkable higher levels when compared to serum after colon surgery. 
The mechanisms of wound healing can be better studied locally than in the circulation.  
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ABSTRACT 
Wound healing is a process with immunological and angiogenic aspects. RhGM-CSF is 
known to stimulate the immune system and angiogenesis via multiple pathways. In this study 
we investigated the combined effects of surgery, with or without rhGM-CSF, on angiogenic 
parameters in patients with a colorectal carcinoma. In this phase II randomized, placebo-
controlled trial, sixteen patients were assigned to perioperative rhGM-CSF (2.8 µg/kg body 
weight) treatment or saline. Patients received subcutaneous injections from three days before 
surgery until four days after. IL-6, VEGF, endostatin and angiostatin levels were measured 
perioperatively. RhGM-CSF enhanced the production of IL-6 and VEGF, but had no effect on 
the anti-angiogenic agents endostatin and angiostatin. Surgery induced a transient decrease of 
endostatin. Two types of angiostatin (kringle 1-3 and kringle 1-4) became visible 
postoperatively. We conclude that this study demonstrated the immediate initiation of 
angiogenesis postoperatively, reflected by the increase of VEGF and a transient decrease of 
endostatin, followed by the appearance of two angiostatin bands, which confirms 
physiological wound healing in these cancer patients. 
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INTRODUCTION 
 
Radical surgery is the initial treatment for patients with primary colorectal carcinoma. 
However, major surgery induces immune suppression and tumor resection may induce 
shedding of tumor cells into the circulation.1 The transient impairment of the host defense 
may be associated with bacterial infections and outgrowth of previous dormant 
micrometastases. RhGM-CSF has been widely used to enhance the number and the activity of 
granulocytes and monocytes, thereby augmenting host defences.2 
Apart from immunological activity, GM-CSF also stimulates migration of endothelial cells 
(ECs) and the formation of new blood vessels from pre-existing vessels, a process known as 
angiogenesis.3,4 This process is tightly regulated by pro-angiogenic and anti-angiogenic 
factors. Among them, vascular endothelial growth factor (VEGF) is considered the most 
potent and specific pro-angiogenic factor.5 VEGF production by cells involved in wound 
healing is partly constitutive, and partly up-regulated by a wide array of external factors, e.g. 
hypoxia, interleukin-6 (IL-6) and GM-CSF.6,7 In addition, peripheral blood cells such as 
platelets and leucocytes contain VEGF, which is released locally after trauma.8  
Theoretically, GM-CSF might also inhibit angiogenesis by activation of macrophages to 
produce matrix metalloproteinase-12 (MMP-12). MMP-12 is capable to cleave angiostatin 
from plasminogen.9 Angiostatin inhibits endothelial cell proliferation in vitro10 and systemic 
administration of angiostatin in a murine model induced regression in breast, prostate and 
colon cancers.11 MMP-12 produced by macrophages may also be involved in the generation 
of endostatin.12 Endostatin induces apoptosis in ECs in vitro13 and potently inhibits tumor 
growth in animal models.14  
In short, GM-CSF is pro-angiogenic by stimulating EC directly and enhancing VEGF 
production. However, GM-CSF may also have anti-angiogenic effects since activated 
macrophages produce enzymes, which may generate angiostatin and endostatin.  
 120
In this randomized study we describe the angiogenic consequences of surgery, with or without 
perioperative rhGM-CSF administration, in patients with a colorectal carcinoma. The immune 
stimulating effects of perioperative rhGM-CSF have been published elsewhere.2 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121 
PATIENTS AND METHODS 
Patients with colorectal cancer without detectable metastases underwent curative surgery and 
were randomized to perioperative treatment with rhGM-CSF or saline. The age of the 
participants was set for minimum 18 years and maximum 75 years. Patients who received 
immunosuppressive medication were excluded. No patients were known to have an 
autoimmune disease. The Ethics Committee of the VU Medical Center, Amsterdam, approved 
the protocol. Informed consent was obtained from all patients. Sixteen patients were enrolled 
in the study, of which eight patients were randomly assigned to the rhGM-CSF group and 
eight patients to the control group. Characteristics of the study population are shown in Table 
1. 
 
Table 1: Characteristics of the study population 
 
 Control group rhGM-CSF group 
Gender (male:female) 
 
Mean age (years) 
    
Astler-Coller (A:B:C) 
    Males 
    Females 
 
Tumor site (Co:S:R) 
     Males 
     Females   
        5 : 3 
 
      64 ± 4 
  
      0 : 8 : 0 
      0 : 5 : 0 
      0 : 3 : 0 
 
      5 : 2 : 1 
      3 : 1 : 1 
      2 : 1 : 0 
          6 : 2 
 
       53 ± 4 
 
       1 : 4 : 3 
       0 : 3 : 3 
       1 : 1 : 0 
 
       3 : 4 : 1 
       3 : 2 : 1 
       0 : 2 : 0 
Age: Mean ± SEM 
Astler Coller:  
   A: tumors with partial wall invasion  
   B: tumors with transmural involvement 
   C: regional lymph node involvemen 
Tumor site:  Co: colon, S: sigmoid, R: rectum 
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Treatment schedule 
All patients were operated through a median laparotomy on day 0. Both groups received daily 
a subcutaneous injection from 3 days (day –3) before, until 4 days  
(day +4) after the operation. The patients received either 1 ml of saline or 2.8 µg/kg  rhGM-
CSF dissolved in 1 ml 0.9% NaCl (Leucomax®, Schering-Plough, Maarssen, The 
Netherlands). 
 
Samples 
Heparinized blood samples were collected on day –4, day 0 (prior to surgery), and day +1 and 
day +6 after the operation. The cytokine samples were centrifuged at 2000 rpm for 10 minutes 
and then stored at -800C. 
 
VEGF 
VEGF concentrations were determined in plasma using an enzyme-linked immunosorbent 
assay (ELISA) kit from R & D system, Minneapolis, U.S.A.. 
The intra- and inter-assay variance was less than 10%. The range of detection of VEGF was 
9.0 - 200 pg/ml. 
 
IL-6 
Plasma IL-6 was measured using an ELISA from Pelikine, CLB, Amsterdam, The 
Netherlands. Normal values are < 10 pg/ml. 
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Endostatin  
Endostatin was measured using an ELISA from Cytimmune, College Park, Maryland, U.S.A.. 
The intra- and inter-assay variance was less than 10%. The range of detection of endostatin 
was 1.95 - 500 ng/ml. 
 
Angiostatin 
Angiostatin was purified by lysine-sepharose affinity chromatography. Briefly, lysine-
sepharose slurry, prepared according to the manufacturer’s instructions (Pharmacia, Uppsala, 
Sweden) was added to plasma samples and incubated under continuous agitation for 15 hours 
at 4°C. After two washes with 50 mM phosphate buffer pH 6.0, bound material was eluted 
with 0.2M ε-amino-capronic acid. Aliquots of 15 µl of eluate (equivalent to 60 µl of plasma) 
plus 15 μl of sample buffer were run on a 10% polyacrylamide gel under non-reducing 
conditions. After electrophoresis, samples were electroblotted onto nitrocellulose membrane, 
blocked, and incubated O/N with affinity-purified rabbit anti-plasminogen kringle 1-3 
antibody (DAKO, Glostrup, Denmark). This antibody recognizes plasminogen as well as both 
angiostatin moieties. After washing, blots were incubated for two hours with swine anti-rabbit 
peroxidase-conjugated secondary antibody (Dako), washed again, and developed by 
chemiluminescence according to the manufacturer’s protocol (Boehringer Mannheim). 
 
STATISTICAL ANALYSIS 
Results are reported as mean ± SEM. The “Statistical Package for the Social Sciences” (SPSS 
7.5tm) was used to analyze data. Differences within groups were analyzed by the Wilcoxon 
Signed Rank Test for two related samples. Differences between the groups at different time 
points were analyzed by means of the two-sample Mann-Whitney test. Significance was 
accepted at a two-tailed P < 0.05. 
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RESULTS 
VEGF, IL-6 and endostatin 
The results are shown in Table 2. RhGM-CSF treatment before surgery had no significant 
effect on these three parameters. One day after surgery VEGF levels were increased in both 
groups, however more pronounced in the rhGM-CSF group (P = 0.02). In the control group 
VEGF levels were increased on day +6, (P = 0.01).  
IL-6 levels were increased in both groups on day +1 (control, P = 0.01), but in the rhGM-CSF 
group the increase was more pronounced (P = 0.02).  
A significant 3 to 4-fold decrease in the endostatin level was found on day +1 in both groups. 
 
 
 
 Treatment 
Group 
 
Day - 4 Day 0 Day +1 Day +6 
VEGF 
 
rhGM-CSF 
 
Control 
 
118 ± 45 
  88 ± 28 
218 ± 73 
  56 ± 12 
637 ± 59 * # 
 
160 ± 55 
166 ± 19 
245 ± 91 * 
IL-6 rhGM-CSF 
 
Control 
11.8 ±16.3  
 
  6.1 ± 0.4 
 
8.8 ± 7.9 
 
6.0 ± 0.0 
 
116 ± 38.4 * 
 
 41.1± 10.2 * 
7.0 ± 2.83 
 
8.1 ± 5.7 
 
Endostatin 
 
 
 
rhGM-CSF 
 
Control 
 
20 ± 2 
 
23 ± 2 
17 ±  5 
 
18 ± 3  
 
4 ± 1 * 
 
5 ± 1 * 
17 ± 2 
 
16 ± 3 
Table 2: Angiogenic growth factors  
   Results: Mean ± SEM 
   VEGF and IL-6 in pg/ml, endostatin in ng/ml 
   * P < 0.05, postoperative value compared to day -4 
    # P < 0.05, rhGM-CSF versus control group 
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Angiostatin 
Angiostatin samples were analyzed by Western blot. Examples of Western blots are shown in 
Figure 1. A prominent plasminogen band at 98 kilo Dalton (kDa), the main source of 
angiostatin, was present in the plasma of all patients. Next to the plasminogen band, in most 
samples a doublet of approximately 55 kDa was observed, whereas in some samples a smear 
between 33-40 kDa with a more discrete band at approximate 37 kDa was present. Based on 
the specificity of the antiserum used, these bands correspond to angiostatin species consisting 
of 4 (K1-4) or 3 (K1-3) kringle domains, respectively. The angiostatin data are summarized in 
Table 3. Whereas a K1-4 angiostatin doublet was absent or vague in most preoperative 
samples, a clear increase in band intensity at day 6 after operation (Figure 1) was observed in 
12 out of 16 patients. Interestingly, the intensity of the K1-4 bands always correlated with the 
intensity of a protein doublet of high (>116 kDa) molecular weight. The identity of these high 
molecular weight bands is unknown. K1-3 angiostatin was also not present in the preoperative 
samples. One day after surgery, however, an intense K1-3 band appeared in 6 out of 16 
samples. Treatment with rhGM-CSF had no effect on the angiostatin patterns of these 
patients. 
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K1-4 angiostatin (50-55 kDa) 
 
K1-3 angiostatin (33-40 kDa) Patient 
Numbera 
Day 
-4 
Day 
0 
Day 
+1 
Day 
+6 
Day 
-4 
Day 
0 
Day 
+1 
Day 
+6 
   1   (+) - - - ++ - - - - 
   2   (+) - - - ++ - - ++ - 
3b  (+) - - - ++ - - +++ - 
   4   (+) + - - - - - ++ - 
   5   (+) n.a. - - + n.a. - - - 
   6   (+) - - + + - - ++ - 
   7   (+) - - - +++ - - - - 
   8b  (+) +++ + ++ +++ - - - - 
   9   (-) - - - - - - - +++ 
  10  (-) - - - ++ - - - - 
  11  (-) - n.a. - ++ - n.a. +++ - 
  12b (-) - - - ++ - - +++ - 
  13  (-) - - - ++ - - - - 
  14  (-) - - - +++ - - - - 
  15b (-) - + - + - - - - 
  16  (-) - - + + - - - - 
Table 3: Intensity of angiostatin bands in perioperative plasma samples of all colorectal  
               carcinoma patients. 
      a: Patients: treated with rhGM-CSF (+); control group (-) 
               b: Patients displayed in figure 1. 
               K1-4 and K1-3 angiostatin expressions was scored semi-quantitatively.  
               Absent and minimal angiostatin expression were scored (-) to very  
               strong (+++) at various time intervals (days; day 0 prior to surgery). 
               n.a.: not available 
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DISCUSSION 
Following radical resection for colorectal carcinoma a number of these patients will develop 
metastatic disease in the liver,15 which largely determines the overall survival of these 
patients. Liver metastases may have been already there in an occult form or induced by 
shedding of cancer cells into the circulation as a result of surgical intervention, and this 
outgrowth may be stimulated by the effect of postoperative immunosuppression, the 
angiogenic response as part of wound healing, or the combination of these effects.1,16 
Perioperative rhGM-CSF has been successfully used in order to enhance the immune status of 
patients with colorectal carcinoma.2 
In the present study we investigated the effects of surgery, with or without perioperative 
rhGM-CSF, on VEGF and IL-6 plasma levels. In both groups VEGF increased after surgery, 
which is in accordance to other observations.17 Tissue hypoxia is the most probable 
explanation for the postoperative VEGF increase. A surgical procedure inevitably causes 
vascular disruption with subsequent reduction of tissue oxygen tension. The observed steep 
and transient increase of VEGF and IL-6 level in the rhGM-CSF group was remarkable. Two 
effects may explain the elevated postoperative levels of VEGF induced by rhGM-CSF. First, 
the surgical trauma itself results in local platelet degranulation and leucocyte sequestration, 
with local VEGF release. The enhanced number and state of activation of leucocytes induced 
by rhGM-CSF might have been responsible for the increased VEGF generation. Second, 
rhGM-CSF induces secondary cytokines, which may affect the VEGF levels.6,18 The elevated 
VEGF level found in the rhGM-CSF group would be expected to have a positive effect on 
wound healing. On the other hand, elevated VEGF levels may have a stimulatory effect on the 
development of micrometastases, demonstrated in an experimental study.19 The involvement 
of VEGF has been further demonstrated in a recent study, where anti-VEGF had a beneficial 
effect in treatment of metastatic colon cancer.20 
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Furthermore, we investigated whether surgery and rhGM-CSF had an effect on endostatin and 
angiostatin levels. These are two endogenous anti-angiogenic factors produced by enzymatic 
digestion of a protein precursor, collagen XVIII and plasminogen, respectively. Collagen 
XVIII has been shown to reside in tissues such as basement membranes, and in the liver.21-23 
In vitro generation of endostatin by elastase and cathepsin L has been demonstrated,12,23 but 
the mechanisms of endostatin generation in vivo are largely unknown. A recent study 
suggested that hepatocytes are the major contributors of circulating endostatin. In addition, 
colon carcinoma may also produce proteases able to properly cleave collagen XVIII present in 
the direct environment.24  
In our study, both groups showed a sharp decrease of endostatin immediately after surgery. 
Various postoperative effects may explain the endostatin decrease. It may concern an effect 
on the production or clearance of endostatin. Since the half-life of endostatin is less than one 
hour, an acute reduction of the production of endostatin by hepatocytes as a negative acute 
phase reaction on stress, or the excision of the tumor could explain an immediate decrease 
after surgery.  
Angiostatin is generated on the endothelial surface from circulating plasminogen. 
Angiostatin bands appeared in the postoperative period. RhGM-CSF treatment did not affect 
the fluctuation of angiostatin levels, as these were similar in both the treated and the control 
group. K1-4 angiostatin became manifest in almost all patients 6 days after surgery, whereas 
the K1-3 form increased transiently in 6/16 of the patients. Both isoforms may function as a 
stopping signal for angiogenesis. Cellular migration during early wound healing is dependent 
on proteolytic enzymes such as matrix metalloproteinases (MMPs) and plasminogen 
activators.25 It is conceivable that the same proteolytic enzymes, involved in early stages of 
wound healing may be responsible for the conversion of plasminogen into the angiostatin 
isoforms at a latter stage.  
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In conclusion, we have demonstrated that rhGM-CSF enhanced IL-6 and VEGF. RhGM-CSF 
had no effect on the production of the anti-angiogenic factors endostatin and angiostatin. 
However, surgery induced a sharp, but transient decrease of endostatin and a significant 
increase of angiostatin. The immediate generation of VEGF and decrease of endostatin, 
followed by the generation of both angiogenesis inhibitors at a later stage of wound healing 
may reflect a physiological tendency to achieve an angiogenic balance, which is characterized 
by initiating and stopping angiogenic signals. 
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ABSTRACT  
Background: Surgery induces a process of wound healing, which has immunological 
and angiogenic aspects. Bactericidal/Permeability-Increasing protein (BPI) is found in 
azurophilic granules of human neutrophils, which is bactericidal and neutralizes 
lipopolysaccharide (LPS). This may reduce postoperative infectious complications. In 
addition, BPI has been shown to be an inhibitor of angiogenesis. 
Methods: A total of 18 patients with metastasized colorectal carcinoma to the liver 
were double blind randomized. The levels of the pro-angiogenic factors interleukin-6 (IL-6) 
and vascular endothelial growth factor (VEGF) and the angiogenesis inhibitor endostatin were 
investigated after liver surgery with perioperative administration of either rBPI21 or placebo. 
Results: The highest IL-6 levels were found during the first 24 hours and reached 
peak levels already at 2 hours postoperatively in both groups. In both groups VEGF levels 
decreased sharply in the postoperative hours, returning to baseline levels in the days 
afterwards. In both groups, an immediate decrease in endostatin levels was observed which 
remained significantly low. RBPI21 transiently influenced IL-6 and VEGF. 
Conclusions: RBPI21 only marginally affected IL-6 and VEGF levels. Surgery per se 
induced an immediate immune response (IL-6) and an immediate angiogenic response, 
reflected in an initial VEGF decrease and a longer lasting decrease of endostatin. These 
findings demonstrate the dynamics of tissue responses in the first phase of wound healing. 
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INTRODUCTION 
Following radical resection for colorectal cancer, still a large number of patients will develop 
liver metastases,1 for which major liver resection is a viable option.2,3 Partial liver resection is 
a major trauma, and is associated with considerable morbidity such as liver failure, 
disseminated intravascular coagulation (DIC) and systemic infections.4,5 We demonstrated 
earlier that continuous perioperative administration of recombinant bactericidal/permeability-
increasing protein (rBPI21) administration in patients undergoing partial liver resection 
resulted in a reduced incidence of postoperative infectious complications.6 BPI is normally 
found in azurophilic granules of human neutrophils and has bactericidal properties against 
gram-negative bacteria and neutralizes lipopolysaccharide (LPS)-mediated effects.7,8 After 
liver surgery, the remnant liver has the ability to regenerate to full size. An important factor in 
the restoration of injured tissue, such as liver regeneration and wound healing is angiogenesis, 
the formation of new blood vessels. Angiogenesis is regulated by a number of specific 
stimulators and inhibitors. A recent study showed that BPI also functions as an angiogenic 
inhibitor.9 Therefore we were interested in the effects of rBPI21 on angiogenic parameters 
after liver surgery. We measured interleukin-6 (IL-6) and VEGF, since both are potent 
angiogenic stimulators and known to be involved in liver regeneration, and endostatin, an 
endogenous angiogenesis inhibitor. 
IL-6 is a multifunctional cytokine, which induces VEGF production10 and is of fundamental 
importance in liver regeneration. A study by Cressman et al, showed that hepatectomy in IL-6 
-/- mice resulted in postoperative liver failure and that IL-6 administration before the 
hepatectomy normalized hepatocyte proliferation postoperatively.11 
VEGF is a potent inducer of angiogenesis, since it stimulates endothelial cell (EC) 
proliferation, migration and vessel formation.12 An increase in VEGF after surgical 
procedures has been observed13,14 and may be directly caused by platelet degranulation or 
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leucocytes which are involved in the repair of injured tissue, or indirectly by hypoxia in 
devitalized tissue and by up-regulation of interleukin-6 (IL-6).10, 13-16 It has been demonstrated 
in an experimental study that hepatocytes produce VEGF, whereas sinusoidal endothelial cells 
express the VEGF receptors, flt-1 and KDR/flk-1, suggesting that VEGF may contribute to 
liver regeneration.17 Taniguchi et al. showed that postoperative VEGF expression was 
associated with hepatocyte proliferation and anti-VEGF inhibited hepatocyte proliferative 
activity after partial hepatectomy in rats.18 
Endostatin is generated from the C-terminal fragment of collagen XVIII.19 Endostatin 
specifically inhibits EC migration in vitro and potently inhibits tumor growth in animal 
models.20 Endostatin can be generated by elastase and cathepsin L in vitro.21,22 The 
mechanism of endostatin generation in vivo is largely unknown. Collagen XVIII has been 
shown to reside in basement membranes and vessel walls.23 A study suggested that 
hepatocytes are a major source of collagen XVIII and may contribute to endostatin levels in 
the circulation.24 
Recombinant BPI (rBPI21) is a 21 kDa  amino-terminal protein derived from the 55 kDa 
human BPI55. RBPI21 has the same bactericidal properties as the endogenous BPI.25,26 The 
main object of this study was to determine the effects of liver surgery on the angiogenic 
profile in the circulation. In addition, the immunologic and angiogenic effects of rBPI21, given 
in a perioperative infusion were studied.  
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MATERIALS AND METHODS 
Patients. This pilot study was part of a phase II, double-blind, placebo-controlled trial in 
patients with metastasized colon carcinoma undergoing a partial hepatectomy (PH). The 
protocol was approved by the Food and Drug Administration, by the Council for Medical 
Research of the Netherlands Organization for Scientific Research, and by the institutional 
review boards or ethical review committees of each participating institution. Informed consent 
was obtained from each patient before entry to this study.  
Study design. A patient’s eligibility for study entry was based on the predefined criteria 
listed in Table 1. The patients were assigned to perioperative treatment with rBPI21 (8 
mg/kg/48hr) or placebo by a 48-hour continuous intravenous infusion starting one hour before 
liver resection. The rBPI21 dose used in this study was based on a previous pharmacokinetic 
study.27  Patients were randomly assigned to treatment (rBPI21 or placebo) by the central 
pharmacist at the VU Medical Center. A computer-generated randomization schedule at a 1:1 
ratio was used. Patients, investigators and clinical monitors remained blinded to individual 
treatment until all data were evaluated. Test articles (rBPI21 and placebo) were supplied by Xoma 
US (LLC, Berkeley, California) as a clear, colorless, sterile non-pyrogenic solution in 10 ml 
glass vials, containing either 2 mg/ml rBPI21 or 0.2 mg/ml human serum albumin (placebo) in 5 
mM sodium citrate/0.15 M sodium chloride buffer, pH 5.0. The rBPI21 solution also contained 
0.2 % poloxamer 188 and 0.002 % polysorbate 80. Until use, the rBPI21 and placebo solutions 
were stored at 2-8 ºC. Before the start of the actual liver resection and study-drug infusion, 
manual exploration and intra-operative ultrasonography were performed to confirm the 
preoperative findings of tumor size and localization. Only when a resection was estimated to be 
≥ 3 liver segments, patients were included and treated with either rBPI21 or placebo in an equal 
volume by 48-hours intravenous infusion. Starting after laparotomy at about 1 hour prior to the 
actual resection of liver tissue, the study medication was administered into a central vein as the 
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sole agent during the course of the infusion. The venous access port was never heparinized, but 
was flushed with physiological saline whenever necessary.  
 
Table 1 
 
Inclusion criteria 
Liver metastases from colon carcinoma 
Age 18-75 yrs. 
Liver resection of ≥ 3 liver segments 
Informed consent 
 
Exclusion criteria 
 
Metastases outside the liver 
Weight >120 kg 
Liver cirrhosis (Child-Pugh class B or C)  
Splenomegaly 
Traumatic liver injury 
Irreversible, fatal underlying disease (including extrahepatic metastases) 
Disease or condition causing immunosuppression 
Anticoagulant therapy < 48 hr prior to surgery 
Immunosuppressive therapy  
Lack of commitment to full life support measures or a “Do Not Resuscitate” (DNR) status 
Known sensitivity to citrate, albumin, poloxomer or polysorbate 
Prior exposure to exogenous BPI  
 
 
 
       Blood sampling. Blood sampling for the measurements of IL-6, VEGF, and endostatin 
was performed preoperatively (baseline values) and at postoperative hour 0 (last suture), 2, 4, 
8 and postoperative days 1, 3, 5, 7 and 9. Upon collection, blood samples were kept on 
melting ice, and plasma was obtained by centrifugation for 10 minutes at 1300g at 4°C. All 
plasma samples were stored in aliquots at -80 ºC until tested.  
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Assessment of total white blood cells (WBC) and platelets  
WBCs including cell differentiation were assessed (Coulter JS, Coulter Electronics, Luton, 
U.K.). Platelet counts were determined using an automated blood coulter counter. Blood 
sampling for measurements of WBC and platelets was performed pre- and postoperatively at 
days 1 and 7. 
 
Assessment of plasma IL-6 
The plasma IL-6 concentration was measured using a commercially available enzyme-linked 
immunosorbent assay (ELISA) kit (Pelikine compact human IL-6 ELISA kit, CLB, 
Amsterdam, the Netherlands). Normal values are < 10 pg/ml 
 
Assessment of plasma VEGF 
VEGF165 concentrations were determined using an ELISA kit (R & D system, Minneapolis, 
USA) according to the manufacturer’s guidelines. The intra- and inter-assay variance was less 
than 10%. The reliable minimum detectable VEGF level is 9.0 pg/ml. 
 
Assesment of plasma endostatin 
Endostatin was measured using a commercially available enzyme-linked immunosorbent 
assay kit (ELISA kit, Cytimmune, College Park, Maryland, USA) according to the 
manufacturer’s guidelines. The intra- and inter-assay variance was less than 10%. The reliable 
minimum detectable endostatin level is 1.95 ng/ml. 
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STATISTICAL ANALYSIS 
The results are reported as means and standard errors of the mean (SEM). The “Statistical 
Package for the Social Sciences” (SPSS 7.5 tm) was used to analyze the data. Overall 
differences between groups were analyzed by means of a one-way analysis of variance, and if 
a significant overall difference between groups was found, the two-sample Mann-Whitney U 
test was used. The Wilcoxon Signed Ranks Test for two related samples analyzed differences 
within groups. Significance was accepted at a two-tailed P < 0.05. 
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RESULTS 
Hemihepatectomy was performed because of metastases of colorectal carcinoma. Of the 31 
patients, 8 were not treated because the tumor was either not resectable (5 patients) or could 
be removed by a small liver resection (3 patients). Five patients were not included due to 
exclusion criteria. A total of 18 patients were eligible for this study: 9 (6 male/ 3 female) 
controls and 9 (7 male/2 female) rBPI21.  
Vascular inflow occlusion by the intermittent Pringle maneuver was used when necessary to 
reduce blood loss during the transection fase. In the control group, 6 required no vascular 
occlusion; the other 3 hemihepatectomy had a mean inflow occlusion time of 79 ± 24 
minutes. In the rBPI21 group, no vascular occlusion was required in 5 patients; the other 4 
liver resection patients had a mean occlusion time of 76 ± 38 minutes. In the control group, 
the mean age was 62.1 ± 2.3 years; the mean operative time was 316.1 ± 26.8 minutes, the 
mean liver resection was 4.4 ± 0.3 segments, perioperative fluid intake 6977.8 ± 561.2 ml, 
perioperative blood loss 2694.4 ± 343.2 ml and the mean hospital stay 25.2 ± 5.1 days. In the 
rBPI21, the mean age was 59.4 ± 2.8 years, the mean operative time 317.7 ± 29.8 minutes, the 
mean liver resection was 4.2 ± 0.2 segments, perioperative fluid intake 7744.4 ± 849.9 ml, 
perioperative blood loss 3025.0 ± 569.8 ml and the mean hospital stay 19.7 ± 3.1 days. No 
significant differences were found between the 2 groups. The administration of  rBPI21 was 
not associated with any side effect. 
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The inflammatory response and platelets  
Total WBCs, the differential leukocyte and platelet counts of both groups are shown in Table 
2. As expected WBC, neutrophils and monocytes significantly increased after surgery in both 
groups. Lymphocytes and platelets significantly decreased at day +1 in both groups.  
Treatment with rBPI21 had no significant effect on these parameters. 
 
 Time RBPI21 Control 
WBC Baseline   7.8 ± 0.7   6.4 ± 0.6 
 Day +1 
 
10.3 ± 0.9*   9.3 ± 0.9* 
 
 
Day +7   9.5 ± 0.9 11.6 ± 2.0* 
Neutr. 
 
Baseline  5.2 ± 0.5  4.6 ± 0.5 
 
 
Day +1  7.6 ± 0.5*  8.5 ± 0.8* 
 
 
Day +7  6.9 ± 0.8  7.1 ± 1.6 
Mono. 
 
Baseline 0.6 ± 0.09 0.5 ± 0.06 
 
 
Day +1 0.7 ± 0.10 0.7 ± 0.07 
 
 
Day +7 0.7 ± 0.98 1.0 ± 0.14* 
Lymph. 
 
Baseline 1.7 ± 0.2 1.4 ± 0.4 
 
 
Day +1 1.0 ± 0.2* 0.8 ± 0.1* 
 
 
Day +7 1.1 ± 0.2 1.1 ± 0.2 
Platelets 
 
Baseline 264 ± 41 257 ± 19 
 
 
Day +1 159 ± 26* 149 ± 10* 
 
 
Day +7 210 ± 25 193 ± 21 
Table 2: Mean ± SEM 
    * P < 0.05, postoperative values when compared with baseline levels 
    WBC (White Blood Cells), Neutrophils, Monocytes, Lymphocytes and platelets in        
    106/ml. 
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Cytokines (Interleukin-6, VEGF, endostatin) 
The interleukin-6, VEGF and endostatin concentrations are shown in Table 3 and 4.  
 
Interleukin-6 
Plasma IL-6 levels were in the normal range preoperatively, but significantly increased in 
both groups in all the postoperative periods. In both groups the highest IL-6 levels were found 
during the first 24 hours and reached peak levels at 2 hours postoperatively. After day +1, the 
IL-6 levels decreased, though levels remained significantly elevated till day +9 in both 
groups. The IL-6 levels in the rBPI21 group were less increased in all postoperative time 
intervals. A difference between the two groups was found 2 hours after surgery, P=0.03. 
 
VEGF 
In both groups VEGF levels decreased significantly in the postoperative hours, whereas in the 
control group the VEGF levels even dropped under the minimum detectable levels. At day +1 
the VEGF levels increased in both groups. The VEGF level in the rBPI21 group was 
significantly higher than the control group, P=0.01, at day +1. 
 
Endostatin 
In both groups, a three to four-fold decrease in endostatin levels was immediately observed, 
which remained significantly low up to day +3. In the control group the endostatin levels were 
still low at day +5, (P=0.04) and +7, (P=0.05) when compared to baseline value. 
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 Time rBPI21 Control 
IL-6 Baseline     2.8 ± 1.9     4.2 ± 2.1 
 0 Hr  174.9 ± 48.8*    252.8 ± 78.4* 
 2 Hr  211.7 ± 52.6* # 527.7 ± 184* # 
 4 Hr  181.1 ± 44.8* 486.9 ± 221* 
 8 Hr  165.5 ± 36.1* 355.8 ± 161* 
 Day +1 168.1 ± 48.9* 133.4 ± 31.3* 
 Day +3   45.3 ± 14.0*   55.9 ± 17.7* 
 Day +5   38.4 ± 13.0*   70.8 ± 29.2* 
 Day +7   25.1 ± 4.9*   48.0 ± 10.8* 
 Day +9   20.2 ± 4.4*   43.9 ± 13.7* 
VEGF Baseline 24.3 ± 3.9               35.2 ± 5.5 
 0 Hr  
 
17.1 ± 3.8* N.D. 
 2 Hr  
 
10.0 ± 4.1* N.D. 
 4 Hr  
 
14.0 ± 4.9* N.D. 
 8 Hr  
 
  9.4 ± 2.1 N.D. 
 Day +1 38.4 ± 6.6# 15.6 ± 3.1*# 
 Day +3 29.8 ± 5.0 19.9 ± 4.8 
 Day +5 24.5 ± 4.5 34.4 ± 10.3 
 Day +7 33.3 ± 7.7 27.1 ± 7.9 
 Day +9 22.9 ± 4.5 24.0 ± 5.1 
Table 3: Mean ± SEM 
   * P < 0.05, postoperative values when compared with baseline levels 
   # P < 0.05, significant difference between the groups 
   N.D. = not detectable, VEGF and IL-6 in pg/ml 
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 Time rBPI21 Control 
Endostatin Baseline 33.1 ± 2.9 36.2 ± 3.2 
 0 Hr  
 
11.3 ± 1.6* 13.2 ± 1.5* 
 2 Hr  
 
14.6 ± 1.6* 15.9 ± 1.3* 
 4 Hr  
 
14.2 ± 2.1* 14.3 ± 1.2* 
 8 Hr  
 
13.6 ± 2.3* 13.5 ± 1.1* 
 Day +1   9.7 ± 1.7*  14.6 ± 1.1*  
 Day +3 15.1 ± 1.9* 14.9 ± 2.3* 
 Day +5 21.7 ± 1.9 21.1 ± 3.3* 
 Day +7 23.3 ± 2.5 17.3 ± 3.1* 
 Day +9 24.5 ± 2.8 21.5 ± 4.6 
Table 4: Mean ± SEM 
   * P < 0.05, postoperative values when compared with baseline levels 
   Endostatin in ng/ml 
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DISCUSSION 
In this study, we measured the inflammatory response reflected by the immune cells and IL-6, 
and the angiogenic response reflected by VEGF and endostatin after partial liver surgery with 
or without perioperative 48-hour continuous rBPI21 administration. 
The postoperative increase of total WBC counts was similar in both groups, which is in 
accordance with other observations.28 Both groups had elevated postoperative IL-6 
concentrations; however, IL-6 levels in the control group were higher than in the rBPI21 
group, suggesting that rBPI21 depresses the IL-6 production. This effect may be explained by 
the LPS-neutralizing capacity of rBPI21. This observation is in accordance with the study by 
Meszaros et al. who demonstrated that the release of pro-inflammatory cytokines IL-1 beta, 
IL-6, IL-8 and tumor necrosis factor, induced by E.coli endotoxin, was tempered by 
administrating rBPI23.26 
Interestingly, IL-6 levels increased and VEGF levels decreased in the postoperative hours in 
both groups. This seems paradoxical since IL-6 can induce VEGF10 and un-physiological as 
well, since VEGF is needed for the initiation of angiogenesis after surgery. The precise 
mechanism for this observation is unclear, but the effect may be explained by experimental 
studies that showed up-regulation of the high affinity VEGF receptors, flt-1 and KDR/flk-1 by 
the endothelium following partial hepatectomy.17,29 In the immediate postoperative period, 
circulatory VEGF and additional VEGF released locally from platelets and leucocytes may be 
scavenged by the up-regulated VEGF receptors, which is needed for an immediate initiation 
of the angiogenic process. The data suggest that the remnant liver endothelium acts as a 
sponge extracting all available VEGF necessary for liver regeneration. Most studies observe 
an increase of circulating VEGF after surgery but studied this at later time points.14,30 We 
demonstrate that profound VEGF physiological dynamics already start in the first 
postoperative hours. 
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After 24-hour continuous rBPI21 administration, VEGF levels are significantly higher when 
compared to the control group on day +1. This observation may be explained by the 
competition of rBPI21 with locally generated VEGF on heparin binding sites in the 
extracellular matrix (ECM), resulting in less storage of VEGF during rBPI21 infusion.9,12 This 
may alter a VEGF concentration gradient that is required for guided EC migration, confirming 
the idea of anti-angiogenic effects of rBPI21. 
The VEGF increase in the later postoperative period may be produced by leucocytes, which 
play an important role in wound healing, as well as hypoxic cells in devitalized tissue and the 
increased IL-6 that can induce VEGF expression.10,16 
Endostatin is an endogenous anti-angiogenic factor. Theoretically, colorectal carcinoma 
metastasized to the liver can generate endostatin by producing proteases able to cleave 
collagen XVIII in the direct environment.31,32 In this study, high preoperative endostatin 
levels were found in cancer patients. This confirms the hypothesis that colon carcinoma 
metastasized to the liver may generate endostatin. Both groups showed a significant 
endostatin decrease immediately after surgery. Multiple factors may be responsible for this 
effect. Removal of the tumor plus a substantial part of the liver means a reduction of 
endostatin production. Surgical trauma with subsequent release of various proteolytic 
enzymes involved in healing of the wound may degrade endostatin. Finally, the effect of 
anesthesia on the liver may inhibit endostatin production. Since the half-life of endostatin is 
less than one hour (Entremed Endostatin manual book), these effects together easily explain 
the immediate decrease after surgery. The postoperative endostatin decrease further 
substantiates the idea that a tumor may produce angiogenic inhibitors, suppressing their 
metastases at distance.33 
In this study, rBPI21 only transiently influenced IL-6 and VEGF production. The most striking 
finding was that surgery per se induced an immediate and impressive immune response (IL-6) 
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together with an immediate angiogenic response, reflected in a paradoxal VEGF decrease and 
a longer lasting decrease of endostatin.  These immediate responses, even the initial, paradoxal 
decrease of VEGF, have a clear physiological meaning and emphasize the importance of 
studying the dynamics of immunological and angiogenic responses in the early phase of 
wound healing. 
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Chapter 8  
GENERAL SUMMARY  
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Since the discovery of angiogenesis by Dr. Folkman in 1971 the explosion of publications 
demonstrated the great importance biomedical researchers attached to this process for human 
biology. However, the knowledge about the effect of a surgical trauma on the local and 
systemic angiogenic balance is limited. 
This thesis aimed to evaluate the angiogenic balance in blood and in local fluid in patients: 
1. Undergoing elective benign or cancer surgery.  
2. Undergoing minimal invasive or conventional surgery. 
3. In whom the angiogenic dynamics were measured at early and later time- 
     intervals. 
4. Who were perioperatively treated with or without immunomodulators. 
This last issue was based on the fact that wounds generate immunologically active cytokines, 
and that the addition of some specific immunological factors might increase (rhGM-CSF, 
chapter 6) or inhibit (rBPI21, chapter 7) the immunological response to surgery. This might 
have consequences for the angiogenic response since many immunological cytokines induce 
also angiogenic effects.  
In Chapter 2 patients with a primary carcinoma were prospectively randomized to a curative 
laparoscopic or conventional colon resection. A difference in both the peritoneal and systemic 
immune response following both surgical approaches was observed. We show evidently that 
the plasma concentrations of pro-inflammatory cytokines after both surgical approaches 
represent only a fraction of what is generated locally. Interestingly the appearance of pro-
inflammatory cytokines in the circulation is significantly lower in the laparoscopic group, 
whereas the same cytokines locally produced showed no differences, confirming the idea that 
both intra-abdominal approaches are different in their impact on the immunological system as 
a whole. In addition, monocyte HLA-DR-expression was measured as a parameter for trauma-
induced immune suppression. A postoperative depression was observed in both groups, but in 
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the conventional group the HLA-DR-expression remained suppressed at least until four 
postoperative days. The cellular response in terms of leucocytes was similar between the two 
groups. Together, subtle differences in the immunological response to a major or minor 
trauma were observed, which warrants further investigation. 
In Chapter 3 we studied the effect of an operative trauma (minimal invasive versus 
conventional Nissen fundoplication) on the circulatory angiogenic balance and the 
inflammatory response. The VEGF plasma level was significantly decreased two hours after 
the operation in the laparoscopic group and returned to preoperative values after 24 hours. In 
the conventional group, the VEGF plasma level significantly increased four days after 
surgery. The white blood cells and C-reactive protein increased rapidly, the latter more 
intensively in the conventional group. The plasma endostatin concentration remained about 
the same in both groups. Again, these findings suggest that the extent of a surgical 
intervention has consequences for the angiogenic and immunological response. 
In Chapter 4 we examined the VEGF and endostatin levels in wound fluid and plasma of 
patients undergoing curative breast cancer surgery and female-to-male mastectomy. We 
compared the angiogenic profile in wound fluid with the pattern in the circulation. In both 
groups VEGF levels in wound fluid were much higher compared to postoperative plasma 
levels, showing a similar trend as was found for pro-inflammatory cytokines in local fluid and 
in plasma. The wound fluid endostatin concentration, however, was lower than in plasma and 
decreased progressively after surgery. The local VEGF increase and endostatin decrease 
observed immediately after surgery appears to be a physiological response to operative 
trauma, since endostatin impairs blood vessel maturation during wound healing. This 
‘angiogenic switch’ was not influenced by the type of process (malignant or benign) involved 
in the surgical intervention. 
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Chapter 5 describes the local and systemic angiogenic profile in patients undergoing curative 
laparoscopic or conventional surgery for colon cancer. Like in chapter 4 the VEGF levels in 
wound fluid were significantly higher compared to postoperative circulatory levels, whereas 
endostatin levels in wound fluid were lower than levels in blood, and decreased progressively 
after surgery in both groups. Interestingly the VEGF levels in wound fluid measured at day 4 
were significantly higher in the laparoscopic group compared with the conventional group. 
This may be explained by the effect of local acidosis, due to CO2 insufflation, on endothelial 
cells.  
In the last two chapters the systemic angiogenic balance was evaluated in patients treated with 
perioperative immunomodulatory agents. Recombinant human GM-CSF is known to 
stimulate the immune system as well as angiogenesis via multiple pathways. In chapter 6 we 
investigated the combined effects of curative surgery, with or without rhGM-CSF, on 
angiogenic parameters in patients with a colorectal carcinoma. In this phase II randomized, 
placebo-controlled trial, patients were assigned to perioperative rhGM-CSF (2.8 µg/kg body 
weight) treatment or saline. RhGM-CSF enhanced the production of IL-6 and VEGF, but had 
no effect on the anti-angiogenic agents endostatin and angiostatin. Surgery induced a transient 
decrease of endostatin. After surgery two types of angiostatin (kringle 1-3 and kringle 1-4) 
became visible in both groups. K1-4 angiostatin became manifest in almost all patients, 
whereas the K1-3 form increased transiently in 6/16 of the patients. This may be explained by 
the fact that proteolytic enzymes, which are part of the coagulation pathway and involved in 
early stages of wound healing, are also active in the conversion of plasminogen into the 
angiostatin. This study suggests an immediate (within 24 hours) initiation of angiogenesis 
postoperatively, reflected by the circulatory increase of VEGF and a transient decrease of 
endostatin, followed by the appearance of two angiostatin bands, which confirms 
physiological wound healing in these cancer patients. 
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BPI is bactericidal and neutralizes lipopolysaccharide (LPS), which may reduce postoperative 
infectious complications. In addition, BPI has been shown to be an inhibitor of angiogenesis. 
In chapter 7 patients with metastasized colorectal carcinoma to the liver were double blind 
randomized. The levels of the pro-angiogenic factors IL-6 and VEGF and the angiogenesis 
inhibitor endostatin were investigated after liver surgery with a 48-hours during, perioperative 
administration of either rBPI21 or placebo. The highest IL-6 levels were found during the first 
24 hours and reached peak levels already at two hours postoperatively in both groups. In both 
groups VEGF levels decreased sharply in the postoperative hours, returning to baseline levels 
in the days afterwards. Also, in both groups, an immediate decrease in endostatin levels was 
observed which remained significantly low. RBPI21 only marginally affected IL-6 and VEGF 
levels. Because blood sampling was performed in the first hours after surgery, it became clear 
that drastic wounding per se induced an immediate immune response (IL-6) and an immediate 
angiogenic response, reflected in an initial VEGF decrease and a longer lasting decrease of 
endostatin. This initial VEGF decrease could be explained by upregulation of the VEGF-
receptors as the very first response to wounding, increasing the uptake of available VEGF, 
followed by an abundant increase in local VEGF production by almost all cells present in the 
wound and, subsequently, an increase in blood VEGF concentrations.  
In conclusion, a surgical trauma elicits a cascade of complex humoral and cellular changes, 
which is intended to protect the host and promote wound healing. For a wound to heal a 
temporary dysequilibrium between angiogenic stimulators and inhibitors occurs. In this thesis 
we demonstrated that a surgical trauma and subsequent wound healing was associated with a 
strong local increase in angiogenic stimulator (VEGF) and a decrease of angiogenic inhibitor 
(endostatin), suggesting a sort of angiogenic switch. The fact that we included surgery for 
patients with a benign or a cancerous process, and the usage of perioperative 
immunomodulators did not heavily influence this physiological process. Due to the fact that 
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we studied locally generated fluid together with blood, we could show that both the 
immunological and the angiogenic consequences of wounding were much more pronounced 
in wound fluid than in the circulation. This suggests that investigation of wound fluid is much 
more informative concerning the process of wound healing than the study of blood. Proteomic 
studies of wound fluid versus blood might be of great interest. In addition, we demonstrated 
that both the immunological response and the angiogenic response were initiated immediately 
after wounding, and showed a pattern which is physiological. The inhibitor generated in tissue 
(endostatin) declined progressively, while enzymatic responses to the formation of an intra-
endothelial clot induced two isoforms of a circulating angiogenesis inhibitor (angiostatin). 
It may be of great interest to investigate the biological significance of the differences in 
surgical interventions (minimal invasive or conventional, concerning different organs or areas 
of the body, different forms of anaesthesia, different types and stages of cancer) for the 
generation of local and circulatory angiogenic stimulators and inhibitors, and their 
consequences for tumor biology. An increased local VEGF may support the proliferation of 
residual tumor cells, and in addition with the immunosuppressive nature of VEGF, which 
inhibits the maturation of dendritic cells, may ultimately result in permission of tumor cell 
outgrowth, locally (graft metastases or local recurrence) or at distance. Anti-angiogenic 
therapy during surgical interventions may have negative consequences for wound healing, 
but, at the same time, may be beneficial for the tumor status of a cancer patient. Different 
angiogenesis inhibitors will vary in their effects on wound healing and anti-tumor activity. 
Timing of these inhibitors during surgery may be of importance. Together, it will be clear that 
further studies are needed to elucidate the process of angiogenesis during wound healing and 
the possible effects of angiogenic factors, generated by surgery, on tumor biology. 
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Angiogenese is het proces van de aanmaak van nieuwe bloedvaten. Dit vindt met name plaats 
in een embryo, maar ook tijdens de menstruatie en wondgenezing en bij ziektes, zoals kanker. 
Angiogenese is ontdekt door Dr. Folkman in 1971 en daarna ontstond een explosie van 
publicaties over dit proces. De kennis van het effect van chirurgisch trauma op angiogenese is 
echter beperkt. Het doel van dit onderzoek was het angiogene evenwicht in bloed en in 
wondvocht van patiënten te evalueren. De patiënten in de onderzoeksgroep voldeden aan èèn 
van de volgende kenmerken:  
1.    Patiënt heeft goedaardige of kanker chirurgie ondergaan  
2.    Patiënt heeft minimaal invasieve of conventionele chirurgie ondergaan  
3. Bij de patiënt is de angiogene dynamiek gemeten, direct na de ingreep en op latere  
       tijdstippen na de ingreep 
4.    Patiënt is perioperatief behandeld met of zonder immunomodulators.  
De aandacht voor het verschil in perioperatieve behandeling is gebaseerd op het feit dat 
wonden cytokinen genereren en dat de toevoeging van sommige specifieke immunologische 
factoren de postoperatieve immunologische respons zou kunnen stimuleren (rhGM-CSF, 
hoofdstuk 6) of remmen (rBPI21, hoofdstuk 7). Dit heeft mogelijk gevolgen voor de 
angiogene respons, want het is bekend dat vele immunologische cytokinen ook angiogene 
effecten hebben.  
In hoofdstuk 2 werden patiënten met darmkanker zonder uitzaaiing prospectief 
gerandomiseerd naar een laparoscopische of conventionele ingreep. Een verschil in zowel de 
lokale (wondvocht) als systemische (plasma) immuunreactie die op beide chirurgische 
benaderingen volgt, werd  opgemerkt. Er wordt aangetoond dat de pro-inflammatoire cytokine 
concentraties gemeten in plasma na beide chirurgische benaderingen slechts een fractie zijn 
van wat er plaatselijk gegenereerd wordt. Opmerkelijk is dat de gemeten expressie van pro-
inflammatoire cytokinen in plasma beduidend lager was na een laparoscopische ingreep, 
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terwijl dezelfde expressie gemeten in wondvocht geen verschillen toonde. Hiermee bevestigen 
we het idee dat beide intra-abdominale benaderingen verschillend zijn in hun uitwerking op 
het immunologische systeem als geheel. Tevens werd HLA-DR-expressie op monocyten 
gemeten, wat als een erkende parameter voor postoperatieve immuunsuppressie fungeert. Een 
postoperatieve suppressie werd in beide groepen opgemerkt, maar in de conventionele groep 
bleef de HLA-DR-expressie onderdrukt tot tenminste vier postoperatieve dagen. De 
postoperatieve leukocytenreactie was gelijk in de twee groepen.  
In hoofdstuk 3 bestudeerden wij het effect van een chirurgisch trauma (laparoscopische versus 
conventionele Nissen fundoplication) op het  angiogene evenwicht in de circulatie en op het 
immuunsysteem. De VEGF concentratie in plasma was twee uur postoperatief beduidend 
lager in de laparoscopische groep en keerde na 24 uur terug naar de preoperatieve waarde. In 
de conventionele groep was de VEGF plasmaconcentratie na vier postoperatieve dagen 
significant toegenomen. De concentratie witte bloedcellen en C-reactief proteïne stegen 
postoperatief snel, waarbij C-reactief proteïne in de conventionele groep sneller toenam dan in 
de laparoscopische  groep. De endostatine concentratie in plasma bleef hetzelfde over de 
gehele periode in beide groepen. Opnieuw heeft de grootte van het chirurgische trauma 
gevolgen voor de angiogene en immunologische reacties.  
In hoofdstuk 4 onderzochten wij VEGF- en endostatine concentraties in wondvocht en plasma 
van patiënten met borstkanker en vrouw-naar-man mastectomie. Wij vergeleken het 
angiogene profiel tussen waarden in wondvocht en in plasma. In beide groepen waren de 
VEGF-concentraties in wondvocht veel hoger dan in plasma. Een soortgelijke trend werd ook 
gevonden voor pro-inflammatoire cytokinen. De endostatine concentratie in wondvocht was 
lager dan in plasma en nam progressief af. De locale VEGF-toename en endostatine afname 
meteen na een chirurgisch ingreep, lijkt een  fysiologisch reactie te zijn op een trauma. Deze 
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postoperatieve 'angiogenic switch' werd niet door het soort proces (maligne of benigne) 
beïnvloed. 
In hoofdstuk 5 onderzochten wij het lokale en systemisch angiogene profiel bij darmkanker 
patiënten die een curatieve laparoscopische of conventionele ingreep ondergingen. Net als in 
hoofdstuk 4 was de VEGF-concentratie in wondvocht beduidend hoger dan de postoperatieve 
VEGF-concentratie in plasma, terwijl de endostatine waarden in wondvocht lager waren dan 
waarden in plasma, en postoperatief progressief afnamen in beide groepen. Op de vierde 
postoperatieve dag was de VEGF-concentratie in wondvocht hoger in de laparoscopische 
groep dan in de conventionele groep. Dit zou verklaard kunnen worden door de gevolgen van 
lokale acidose, tengevolge van CO2-insufflatie, op endotheel cellen.  
In de laatste twee hoofdstukken evalueerden we de angiogene balans in het bloed van 
patiënten die perioperatief behandeld werden met een immunomodulerend middel. Het is 
bekend dat GM-CSF zowel het immuunsysteem als de angiogenese stimuleert.  
In hoofdstuk 6 onderzochten wij de gecombineerde effecten van chirurgie en rhGM-CSF, op 
angiogene parameters bij patiënten met darmkanker. In deze fase II ge-randomiseerde, 
placebo-gecontroleerde studie werden patiënten perioperatief behandeld met rhGM-CSF (2,8 
mg/kg lichaamsgewicht) of met fysiologisch zout. rhGM-CSF versterkte de productie van IL-
6 en VEGF, maar had geen invloed op endostatine en angiostatine. De chirurgische ingreep 
induceerde een kortdurende endostatine afname. In beide groepen verschenen na de ingreep 
twee soorten angiostatine (kringle 1-3 en kringle 1-4). K1-4 angiostatine werd manifest in 
bijna alle patiënten en K1-3 angiostatine nam in 6 van de 16 patiënten toe. Een mogelijke 
verklaring hiervoor is dat proteolytische enzymen, die in het vroege wondgenezingsstadium 
actief worden, ook betrokken zijn in de conversie van plasminogeen naar angiostatine. 
Samenvattend wordt de angiogenese in een vroeg postoperatief stadium geïnitieerd door 
toename van VEGF en afname van een angiogenese-remmer (endostatine), gevolgd door de 
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verschijning van twee angiostatine banden. Dit patroon bevestigt dat het 
wondgenezingsproces bij kankerpatiënten fysiologisch verloopt. Postoperatieve infectueuze 
complicaties kunnen mogelijk worden verminderd door het bactericidal permeability 
increasing protein (BPI), dat lipopolysaccharide (LPS) neutraliseert. Bovendien is aangetoond 
dat BPI een anti-angiogene werking heeft. 
In hoofdstuk 7 werden patiënten met levermetastasen bij darmkanker perioperatief behandeld 
met rBPI21 of een placebo. De pro-angiogene factoren IL-6, VEGF en de anti-angiogene 
factor endostatine werden gemeten. In beide groepen werden in de eerste 24 uur de hoogste 
IL-6 concentraties gemeten met een piek twee uur na de ingreep. In beide groepen werd 
tevens in de eerste postoperatieve uren een sterke VEGF-daling waargenomen en in de dagen 
erna nam de VEGF-concentratie toe. De VEGF-afname zou mogelijk verklaard kunnen 
worden door een acute expressie van VEGF-receptoren, waardoor circulerend VEGF wordt 
weggevangen. De toename van VEGF daarna wordt geproduceerd door alle cellen die 
betrokken zijn in het wondgenezingsproces. Recombinant BPI21 had marginale invloed op IL-
6 en VEGF. Ook in beide groepen werd een acute endostatine afname waargenomen.  
Sammenvattend start een chirurgisch trauma een cascade van complexe humorale en 
cellulaire veranderingen die zijn gastheer beschermen en de  wondgenezing bevorderen. Bij 
een wond zal een tijdelijke disbalans ontstaan tussen angiogene stimulatoren en remmers. In 
dit proefschrift demonstreerden wij dat wondgenezing gepaard gaat met een sterke lokale pro-
angiogene (VEGF) toename en lokale afname van een anti-angiogene factor (endostatine), 
wat lijkt op een lokale "angiogenic switch". Dit fenomeen treedt op na een chirurgische 
ingreep bij zowel patiënten met als zonder kanker en wordt niet beïnvloed door het gebruik 
van perioperatieve immunomodulatoren. Door het tegelijk bestuderen van wondvocht en 
plasma toonden we aan dat zowel de immunologische als de angiogene reacties meer 
uitgesproken zijn in wondvocht dan in de circulatie. Bestudering van het 
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wondgenezingsproces via het wondvocht levert kennelijk betere informatie op dan 
bestudering van factoren in het bloed. Tevens demonstreerden wij dat zowel de 
immunologische als de angiogene reacties onmiddellijk na een verwonding beginnen. Het is 
interessant de biologische betekenis van lokale en circulerende angiogene factoren na 
verschillende chirurgische interventies te onderzoeken. Bijvoorbeeld na een laparoscopische 
of conventionele ingreep, in verschillende organen of gebieden van het lichaam, de invloeden 
van anesthesie en bij verschillende typen en stadia van kanker. De consequenties voor de 
tumorbiologie zijn hierbij bijzonder interessant. Het gebruik van anti-angiogene therapie 
tijdens een chirurgische ingreep valt te overwegen. De combinatie van anti-angiogene 
therapie en chirurgie zou negatieve gevolgen kunnen hebben voor de wondgenezing, maar 
tegelijkertijd heilzaam kunnen zijn voor patiënten met kanker. De verschillende angiogenese 
remmers zullen mogelijk in hun gevolgen voor wondgenezing en anti-tumor activiteit 
variëren. Bij het gebruik van deze remmers tijdens chirurgie is optimale timing van groot 
belang. Vanzelfsprekend zijn er meer studies nodig om het angiogenese proces tijdens 
wondgenezing verder te doorgronden en de mogelijke biologische effecten van angiogene 
factoren, die door een chirurgisch ingreep gegenereerd worden, op tumorbiologie in kaart te 
brengen.   
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